MeSH term
Frequency | Condition_Probility | Acute Disease | 16 | 0.0 |
Adult | 265 | 0.0 |
Comparative Study | 132 | 0.0 |
Humans | 1531 | 0.0 |
United States/epidemiology | 5 | 1.0 |
Antihypertensive Agents/therapeutic use | 2 | 2.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Diabetes Mellitus, Type 2/*epidemiology/prevention & control | 2 | 7.0 |
*Diet, Reducing | 2 | 2.0 |
*Exercise | 2 | 1.0 |
Incidence | 5 | 0.0 |
Male | 279 | 0.0 |
Middle Aged | 173 | 0.0 |
Reference Values | 15 | 0.0 |
Risk Factors | 22 | 0.0 |
Smoking/adverse effects | 2 | 0.0 |
*Smoking Cessation | 2 | 5.0 |
Weight Loss | 2 | 1.0 |
Aged | 72 | 0.0 |
Time Factors | 68 | 0.0 |
Animals | 402 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 2 | 2.0 |
DNA Adducts | 2 | 2.0 |
DNA Damage | 2 | 0.0 |
DNA Repair | 2 | 0.0 |
Drug Delivery Systems | 3 | 3.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Gene Expression | 41 | 0.0 |
Neoplasms/drug therapy/genetics | 2 | 6.0 |
Platinum Compounds/*pharmacology/therapeutic use | 2 | 7.0 |
Anxiety Disorders/*classification/psychology/therapy | 2 | 22.0 |
Child | 48 | 0.0 |
Alleles | 72 | 0.0 |
Research Support, Non-U.S. Gov't | 1065 | 0.0 |
Variation (Genetics) | 38 | 2.0 |
Prevalence | 10 | 0.0 |
Chronic Disease | 13 | 0.0 |
Female | 287 | 0.0 |
Genetic Heterogeneity | 2 | 0.0 |
Graft Rejection/*genetics | 2 | 18.0 |
*Kidney Transplantation | 4 | 0.0 |
*Polymorphism, Genetic | 44 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 659 | 1.0 |
Transplantation, Homologous | 7 | 1.0 |
Th1 Cells/*immunology | 13 | 9.0 |
Up-Regulation/*immunology | 6 | 11.0 |
Antibodies, Monoclonal/immunology/pharmacology | 3 | 3.0 |
Cell Movement/drug effects/immunology | 3 | 21.0 |
Cell Transformation, Viral | 2 | 0.0 |
Cells, Cultured | 289 | 1.0 |
*Chemotaxis | 3 | 9.0 |
Flow Cytometry | 157 | 2.0 |
Homozygote | 40 | 2.0 |
Neutralization Tests | 34 | 7.0 |
Receptors, CCR5/genetics/immunology/*metabolism | 5 | 100.0 |
Fetus | 9 | 1.0 |
Kidney Transplantation | 4 | 3.0 |
Leukocytes/immunology | 3 | 2.0 |
Receptors, CCR5/analysis | 36 | 73.0 |
T-Lymphocytes/cytology/drug effects/*immunology | 2 | 7.0 |
Up-Regulation/drug effects | 7 | 1.0 |
DNA, Complementary/genetics | 3 | 0.0 |
HIV-1/*pathogenicity/physiology | 11 | 35.0 |
Receptors, CCR5/genetics/physiology | 5 | 71.0 |
Receptors, CXCR4/genetics/physiology | 5 | 83.0 |
Receptors, HIV/genetics/*physiology | 5 | 62.0 |
Transfection | 98 | 0.0 |
Cell Membrane/metabolism | 21 | 1.0 |
Endoplasmic Reticulum/metabolism | 4 | 1.0 |
Fluorescent Antibody Technique | 21 | 0.0 |
Receptors, CCR5/agonists/*metabolism | 4 | 100.0 |
Administration, Oral | 8 | 0.0 |
Anti-HIV Agents/*chemical synthesis/chemistry/pharmacology | 3 | 27.0 |
Biological Availability | 4 | 1.0 |
Cell Line | 277 | 1.0 |
HIV-1/drug effects/isolation & purification | 3 | 27.0 |
In Vitro | 50 | 0.0 |
Leukocytes, Mononuclear/drug effects/virology | 5 | 71.0 |
Mice | 138 | 0.0 |
Piperidines/*chemical synthesis/chemistry/pharmacology | 2 | 50.0 |
Radioligand Assay | 8 | 1.0 |
Rats | 33 | 0.0 |
Receptors, CCR5/*antagonists & inhibitors | 34 | 100.0 |
Structure-Activity Relationship | 54 | 1.0 |
Virus Replication/drug effects | 34 | 14.0 |
Blotting, Western | 14 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 24 | 0.0 |
HIV Infections/etiology | 4 | 40.0 |
Macaca mulatta | 41 | 9.0 |
Monocytes/*virology | 8 | 34.0 |
Morphine/*pharmacology | 3 | 14.0 |
Narcotics/*pharmacology | 4 | 26.0 |
Receptors, CCR5/*biosynthesis | 22 | 91.0 |
SIV/*physiology | 12 | 44.0 |
Virus Replication/*drug effects | 24 | 15.0 |
CD4-CD8 Ratio | 11 | 1.0 |
Cross-Sectional Studies | 16 | 1.0 |
Macrophage Inflammatory Protein-1/pharmacology | 24 | 54.0 |
RANTES/pharmacology | 32 | 60.0 |
RNA, Messenger/metabolism | 29 | 0.0 |
Receptors, Chemokine/*biosynthesis | 15 | 38.0 |
Surface Properties | 3 | 1.0 |
Anti-HIV Agents/*chemistry/*pharmacology | 3 | 37.0 |
Binding Sites | 49 | 0.0 |
Capsid/drug effects | 3 | 100.0 |
*Capsid Proteins | 4 | 3.0 |
Drug Design | 9 | 2.0 |
Gene Products, gag/drug effects | 3 | 75.0 |
HIV/*drug effects/genetics/physiology | 2 | 40.0 |
HIV Envelope Protein gp120/drug effects | 2 | 33.0 |
HIV Envelope Protein gp41/drug effects | 2 | 66.0 |
HIV Infections/*drug therapy | 12 | 5.0 |
HIV Integrase Inhibitors/chemistry/pharmacology | 3 | 100.0 |
HIV Protease Inhibitors/chemistry/pharmacology | 3 | 60.0 |
Molecular Structure | 14 | 1.0 |
Receptors, HIV/antagonists & inhibitors | 2 | 50.0 |
Reverse Transcriptase Inhibitors/chemistry/pharmacology | 3 | 100.0 |
*Viral Proteins | 4 | 2.0 |
Epithelial Cells/metabolism/*virology | 2 | 66.0 |
HIV-1/*physiology | 117 | 24.0 |
Receptors, CXCR4/*analysis | 8 | 61.0 |
Virus Replication | 122 | 14.0 |
Base Sequence | 97 | 0.0 |
*Cell Adhesion Molecules | 7 | 3.0 |
HIV-1/*metabolism | 42 | 18.0 |
*Lectins, C-Type | 9 | 5.0 |
Molecular Sequence Data | 263 | 0.0 |
RNA, Messenger/analysis | 35 | 1.0 |
Receptors, Chemokine/genetics/*metabolism | 22 | 46.0 |
Receptors, Virus/genetics/*metabolism | 4 | 12.0 |
Reverse Transcriptase Polymerase Chain Reaction | 57 | 0.0 |
Sequence Alignment | 40 | 0.0 |
Anti-HIV Agents/*pharmacology | 42 | 30.0 |
HIV Infections/virology | 23 | 32.0 |
HIV-1/*drug effects/physiology | 15 | 17.0 |
Macrophages/*drug effects/metabolism/virology | 2 | 100.0 |
Ritonavir/pharmacology | 2 | 16.0 |
Cell Differentiation | 29 | 0.0 |
HIV Infections/physiopathology/*virology | 2 | 40.0 |
Infant | 36 | 0.0 |
Infant, Newborn | 22 | 0.0 |
Interleukins/*pharmacology | 2 | 2.0 |
Receptors, CCR5/metabolism | 112 | 75.0 |
Receptors, CXCR4/metabolism | 69 | 44.0 |
T-Lymphocytes/physiology/virology | 2 | 50.0 |
Thymus Gland/cytology/*virology | 2 | 33.0 |
Calcium Signaling/*physiology | 2 | 4.0 |
*Cytokines | 7 | 18.0 |
Lymphocyte Activation | 55 | 1.0 |
Polymerase Chain Reaction | 71 | 0.0 |
Receptors, Chemokine/*physiology | 9 | 21.0 |
Recombinant Proteins/metabolism | 19 | 0.0 |
Sequence Deletion | 34 | 1.0 |
Substrate Specificity | 8 | 0.0 |
*Chemotaxis, Leukocyte | 5 | 6.0 |
Cytokines/biosynthesis | 13 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 69 | 0.0 |
Case-Control Studies | 29 | 0.0 |
Cell Movement/drug effects/physiology | 2 | 3.0 |
Down-Regulation | 42 | 2.0 |
Immunoblotting | 5 | 0.0 |
Lymphocyte Activation/drug effects | 6 | 1.0 |
RANTES/*pharmacology | 12 | 70.0 |
Sensitivity and Specificity | 6 | 0.0 |
T-Lymphocytes/drug effects/immunology | 2 | 2.0 |
CD4-Positive T-Lymphocytes/*metabolism/virology | 2 | 18.0 |
English Abstract | 18 | 0.0 |
HIV Infections/immunology/metabolism/virology | 2 | 66.0 |
Receptors, CCR5/*metabolism | 137 | 91.0 |
Receptors, CXCR4/*metabolism | 79 | 49.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Receptors, Chemokine/*biosynthesis/genetics | 10 | 34.0 |
Receptors, HIV/*biosynthesis/genetics | 2 | 66.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism | 2 | 3.0 |
Chemotaxis, Leukocyte/immunology | 12 | 20.0 |
Immunologic Memory/immunology | 4 | 10.0 |
Interphase/immunology | 5 | 10.0 |
Ligands | 80 | 2.0 |
Lymphocyte Activation/*immunology | 4 | 0.0 |
Macrophage Inflammatory Protein-1/*physiology | 3 | 100.0 |
Protein Binding/immunology | 6 | 3.0 |
RANTES/*physiology | 3 | 50.0 |
Receptors, Chemokine/biosynthesis/*physiology | 2 | 28.0 |
Signal Transduction/*immunology | 8 | 2.0 |
T-Lymphocyte Subsets/immunology/metabolism | 3 | 6.0 |
Amino Acid Sequence | 226 | 0.0 |
Calcium/blood | 2 | 0.0 |
Chemotaxis, Leukocyte/*physiology | 3 | 9.0 |
Lymphocytes/immunology | 3 | 0.0 |
Phylogeny | 37 | 2.0 |
RANTES/genetics | 6 | 40.0 |
Sequence Homology, Amino Acid | 53 | 0.0 |
Chemokines, CC/*pharmacology | 8 | 38.0 |
Chemotactic Factors/pharmacology | 2 | 6.0 |
Chemotaxis, Leukocyte/physiology | 2 | 10.0 |
Eosinophils/drug effects/*immunology | 2 | 22.0 |
Kinetics | 49 | 0.0 |
Macrophage Inflammatory Protein-1/*pharmacology | 8 | 53.0 |
Antigens, CD45/analysis | 9 | 3.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism/virology | 3 | 30.0 |
*Immunologic Memory | 7 | 5.0 |
T-Lymphocyte Subsets/*immunology/metabolism/*virology | 2 | 100.0 |
CD4 Lymphocyte Count | 50 | 2.0 |
HIV-1/genetics/immunology/*physiology | 2 | 16.0 |
Receptors, CCR5/genetics/*metabolism | 38 | 95.0 |
DNA Primers | 29 | 0.0 |
HIV Envelope Protein gp120/chemistry | 3 | 42.0 |
HIV-1/*genetics | 12 | 3.0 |
Macrophages | 3 | 3.0 |
Peptide Fragments/chemistry | 5 | 2.0 |
Phenotype | 87 | 0.0 |
Amino Acid Motifs | 5 | 0.0 |
*Apoptosis/drug effects | 5 | 4.0 |
Jurkat Cells | 19 | 1.0 |
Leukocytes, Mononuclear/immunology | 11 | 4.0 |
Cell Line, Tumor | 12 | 0.0 |
Cross Reactions | 5 | 0.0 |
Hela Cells | 82 | 1.0 |
Peptide Library | 4 | 3.0 |
Receptors, CCR5/chemistry/immunology/*metabolism | 2 | 100.0 |
Blotting, Western/methods | 2 | 1.0 |
Cell Movement/drug effects | 6 | 1.0 |
Dose-Response Relationship, Drug | 42 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Oligonucleotide Array Sequence Analysis/methods | 3 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 6 | 1.0 |
Calcium Signaling | 7 | 8.0 |
Cell Division/drug effects | 8 | 0.0 |
Cell-Free System | 2 | 0.0 |
Coculture Techniques | 29 | 4.0 |
Mitogens/pharmacology | 2 | 0.0 |
Rabbits | 17 | 0.0 |
Temperature | 6 | 0.0 |
Calcium Signaling/drug effects | 6 | 12.0 |
Cyclodextrins/pharmacology | 2 | 7.0 |
Excipients/pharmacology | 2 | 50.0 |
Macrophage Inflammatory Protein-1/*metabolism | 18 | 85.0 |
Protein Binding/drug effects | 6 | 1.0 |
Receptors, CCR5/chemistry/*metabolism | 11 | 100.0 |
Tumor Cells, Cultured | 72 | 0.0 |
*beta-Cyclodextrins | 3 | 7.0 |
Cloning, Molecular | 39 | 0.0 |
HIV Infections/*virology | 34 | 34.0 |
HIV-1/genetics/*pathogenicity | 6 | 31.0 |
HIV Infections/blood/*virology | 2 | 18.0 |
*Virus Replication | 31 | 11.0 |
Genetic Complementation Test | 3 | 0.0 |
HIV-1/genetics/*physiology | 18 | 16.0 |
Kenya | 2 | 4.0 |
*Membrane Fusion | 9 | 24.0 |
Receptors, CCR5/*physiology | 39 | 95.0 |
HIV/*physiology | 8 | 10.0 |
Immunohistochemistry | 43 | 0.0 |
Microglia/*virology | 4 | 80.0 |
Papio | 2 | 1.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Receptors, Chemokine/genetics/*physiology | 4 | 36.0 |
Chondroitin Sulfates/metabolism | 2 | 6.0 |
Dogs | 15 | 1.0 |
Membrane Fusion/*physiology | 10 | 38.0 |
Serine/metabolism | 3 | 0.0 |
Kidney/*metabolism | 2 | 1.0 |
Kidney Glomerulus/metabolism/pathology | 2 | 16.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
NF-kappa B/*metabolism | 3 | 0.0 |
Phosphorylation | 24 | 0.0 |
Signal Transduction | 38 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Antigens, CD4/*metabolism | 38 | 11.0 |
HIV-1/genetics/*pathogenicity/physiology | 5 | 31.0 |
Macrophages/immunology/*virology | 5 | 38.0 |
Recombinant Proteins/pharmacology | 16 | 0.0 |
Antigens, CD27/analysis | 2 | 11.0 |
Antigens, CD28/analysis | 2 | 5.0 |
Cytotoxicity, Immunologic | 4 | 0.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Immunophenotyping | 29 | 0.0 |
Receptors, Chemokine/analysis | 9 | 30.0 |
T-Lymphocyte Subsets/*immunology | 6 | 1.0 |
Antigens, CD45/*analysis | 3 | 6.0 |
Receptors, Chemokine/*analysis | 18 | 50.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Gene Expression/drug effects | 4 | 0.0 |
Naloxone/pharmacology | 2 | 4.0 |
Narcotic Antagonists/pharmacology | 2 | 18.0 |
Chemokines/*metabolism | 17 | 30.0 |
Chemokines, CC/metabolism | 14 | 32.0 |
Chemotaxis, Leukocyte/*immunology | 4 | 8.0 |
Gene Expression Regulation/immunology | 7 | 4.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Macrophage Inflammatory Protein-1/metabolism | 32 | 57.0 |
Monocyte Chemoattractant Protein-1/metabolism | 14 | 22.0 |
RANTES/metabolism | 31 | 50.0 |
Receptors, CCR5/*genetics | 143 | 88.0 |
Receptors, Chemokine/metabolism | 36 | 31.0 |
AIDS Dementia Complex/*virology | 4 | 66.0 |
Antigens, CD4/metabolism | 59 | 19.0 |
Brain/virology | 4 | 30.0 |
Giant Cells/physiology | 6 | 35.0 |
HIV Envelope Protein gp160/chemistry/genetics | 2 | 100.0 |
HIV-1/isolation & purification/*pathogenicity | 3 | 75.0 |
Macrophages/virology | 39 | 52.0 |
Monocytes/virology | 8 | 28.0 |
Organ Culture Techniques | 4 | 1.0 |
Virulence | 13 | 5.0 |
Cohort Studies | 61 | 2.0 |
Genetic Predisposition to Disease | 25 | 1.0 |
*Heterozygote | 8 | 2.0 |
Homosexuality, Male | 14 | 14.0 |
Mutation | 43 | 0.0 |
Receptors, Chemokine/*genetics | 47 | 47.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Interleukin-12/biosynthesis | 3 | 3.0 |
Receptors, Cell Surface/metabolism | 5 | 1.0 |
*Receptors, Lipoxin | 5 | 14.0 |
Up-Regulation | 25 | 1.0 |
African Continental Ancestry Group/genetics | 7 | 2.0 |
Disease Progression | 80 | 2.0 |
European Continental Ancestry Group/genetics | 12 | 1.0 |
Evolution, Molecular | 14 | 1.0 |
Gene Frequency | 48 | 1.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Haplotypes/genetics | 4 | 0.0 |
Linkage Disequilibrium/genetics | 2 | 1.0 |
Models, Genetic | 5 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Receptors, Chemokine/genetics | 17 | 36.0 |
Regression Analysis | 3 | 0.0 |
Selection (Genetics) | 4 | 3.0 |
Variation (Genetics)/genetics | 3 | 1.0 |
Antibodies, Monoclonal/immunology | 25 | 1.0 |
Antibody Affinity | 2 | 1.0 |
Antigens, CD4/*immunology | 7 | 2.0 |
Binding, Competitive | 32 | 1.0 |
Cell Fusion | 30 | 12.0 |
Cell Membrane/immunology | 4 | 1.0 |
Gene Products, env/immunology | 3 | 10.0 |
HIV Antibodies/*immunology | 6 | 6.0 |
HIV Envelope Protein gp120/*immunology | 7 | 5.0 |
HIV-1/*immunology/isolation & purification | 3 | 11.0 |
Receptors, CCR5/*immunology | 16 | 88.0 |
Macrophages/metabolism | 12 | 3.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Receptors, Chemokine/*metabolism | 61 | 42.0 |
Receptors, HIV/metabolism | 16 | 50.0 |
Chemokines, CC/blood | 2 | 50.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 6 | 17.0 |
CD4-Positive T-Lymphocytes/*drug effects/metabolism | 2 | 22.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Acquired Immunodeficiency Syndrome/genetics | 2 | 50.0 |
Chemokines, CXC/*genetics | 10 | 31.0 |
Genotype | 136 | 1.0 |
HIV Infections/genetics | 8 | 80.0 |
HIV-1 | 16 | 8.0 |
*AIDS Vaccines | 3 | 25.0 |
Anti-HIV Agents/pharmacology | 16 | 35.0 |
HIV Protease Inhibitors/pharmacology | 3 | 23.0 |
Macaca | 9 | 10.0 |
Membrane Fusion/drug effects | 9 | 27.0 |
Receptors, CCR5/physiology | 19 | 61.0 |
Receptors, CXCR4/drug effects/physiology | 3 | 100.0 |
Reverse Transcriptase Inhibitors/pharmacology | 4 | 26.0 |
SIV/physiology | 2 | 16.0 |
Antigens, Surface/metabolism | 2 | 1.0 |
Blood Cells/metabolism | 2 | 6.0 |
Cell Movement | 18 | 2.0 |
Chemokines/*physiology | 9 | 29.0 |
Cytokines/pharmacology | 13 | 3.0 |
Membrane Proteins/physiology | 2 | 2.0 |
Anti-HIV Agents/*therapeutic use | 9 | 2.0 |
Disease Models, Animal | 14 | 0.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
HIV Infections/*drug therapy/virology | 3 | 3.0 |
*HIV-1/physiology | 3 | 16.0 |
Viral Load | 41 | 4.0 |
Antigens, CD95/immunology | 2 | 3.0 |
Apoptosis/*immunology | 3 | 1.0 |
CD4-Positive T-Lymphocytes/immunology | 23 | 2.0 |
CD8-Positive T-Lymphocytes/immunology | 14 | 2.0 |
Lymphocyte Subsets/*immunology | 2 | 1.0 |
Monocytes/*immunology | 2 | 0.0 |
Receptors, CCR5/immunology | 18 | 94.0 |
Receptors, Chemokine/immunology | 11 | 34.0 |
Th1 Cells/immunology | 8 | 4.0 |
Acquired Immunodeficiency Syndrome/*transmission | 2 | 20.0 |
Adolescent | 58 | 0.0 |
*Disease Transmission, Vertical | 12 | 12.0 |
HIV Envelope Protein gp120/chemistry/genetics | 6 | 50.0 |
Peptide Fragments/chemistry/genetics | 6 | 22.0 |
Pregnancy | 27 | 0.0 |
*HIV-1 | 92 | 9.0 |
Haplotypes | 15 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
RNA, Viral/*blood | 5 | 3.0 |
Arthritis, Rheumatoid/*immunology | 6 | 2.0 |
Cell Movement/immunology | 9 | 9.0 |
Chemokines/metabolism | 17 | 23.0 |
Immunologic Memory | 21 | 7.0 |
T-Lymphocytes/*immunology | 19 | 0.0 |
Blood Donors | 7 | 3.0 |
Heterozygote | 31 | 1.0 |
COS Cells | 17 | 0.0 |
Cattle | 7 | 0.0 |
Genes, Reporter | 14 | 0.0 |
Protein Structure, Secondary | 17 | 1.0 |
Receptors, CCR5/*chemistry/genetics/metabolism | 3 | 100.0 |
Receptors, HIV/chemistry/*metabolism | 3 | 75.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
DNA, Viral/genetics | 5 | 3.0 |
Disease Transmission, Vertical | 12 | 13.0 |
HIV Envelope Protein gp120/genetics | 15 | 44.0 |
Peptide Fragments/genetics | 11 | 16.0 |
Pregnancy Complications, Infectious/*virology | 2 | 15.0 |
CD4-Positive T-Lymphocytes/drug effects/metabolism | 4 | 30.0 |
Calcium/metabolism | 52 | 3.0 |
Drug Synergism | 6 | 0.0 |
Monocyte Chemoattractant Proteins/*pharmacology | 3 | 60.0 |
Pertussis Toxin | 7 | 4.0 |
Virulence Factors, Bordetella/pharmacology | 7 | 3.0 |
CD4-Positive T-Lymphocytes/*chemistry | 3 | 18.0 |
Child, Preschool | 28 | 0.0 |
Receptors, CCR5/*analysis | 16 | 84.0 |
Antigens, CD/analysis | 7 | 0.0 |
Chemotaxis/immunology | 5 | 35.0 |
Models, Animal | 2 | 0.0 |
Astrocytes/cytology/virology | 3 | 75.0 |
Prospective Studies | 13 | 0.0 |
Receptors, HIV/*metabolism | 32 | 50.0 |
CHO Cells/drug effects/metabolism | 2 | 14.0 |
Cell Adhesion/drug effects | 7 | 1.0 |
Chelating Agents/pharmacology | 3 | 3.0 |
Cricetulus | 5 | 1.0 |
Hamsters | 59 | 1.0 |
Recombinant Fusion Proteins/physiology | 5 | 1.0 |
Antigens, CD45/metabolism | 4 | 4.0 |
CD4-Positive T-Lymphocytes/metabolism | 9 | 7.0 |
Lymphocyte Count | 15 | 2.0 |
T-Lymphocytes/*metabolism | 11 | 2.0 |
*Down-Regulation | 6 | 1.0 |
HIV Infections/prevention & control | 4 | 26.0 |
Monocytes/immunology/*metabolism | 3 | 6.0 |
Gene Expression Regulation | 19 | 0.0 |
HIV Infections/immunology/virology | 7 | 26.0 |
Microglia/virology | 3 | 60.0 |
Th2 Cells/metabolism | 3 | 7.0 |
Amino Acid Substitution | 18 | 1.0 |
HIV Envelope Protein gp120/chemistry/*genetics | 3 | 42.0 |
HIV-1/classification/*genetics | 5 | 23.0 |
Models, Molecular | 36 | 1.0 |
Peptide Fragments/chemistry/*genetics | 2 | 40.0 |
Protein Conformation | 40 | 1.0 |
*Variation (Genetics) | 15 | 1.0 |
Cats | 6 | 1.0 |
Genes, env/genetics | 4 | 33.0 |
Leukocytes, Mononuclear/virology | 30 | 28.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
*Zoonoses | 2 | 66.0 |
Antigens, CD4/*chemistry/genetics/*metabolism | 2 | 22.0 |
HIV Envelope Protein gp120/metabolism/*pharmacology | 3 | 33.0 |
Mutagenesis, Site-Directed | 35 | 1.0 |
Protein Structure, Tertiary | 19 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Interleukin-4/metabolism | 3 | 3.0 |
Mice, Inbred BALB C | 18 | 0.0 |
Mice, Inbred CBA | 2 | 0.0 |
Spleen/metabolism | 3 | 2.0 |
Russia/epidemiology | 2 | 8.0 |
*Sequence Deletion | 8 | 2.0 |
Antigens, Surface/biosynthesis | 2 | 3.0 |
Down-Regulation/drug effects | 12 | 4.0 |
Macrophages/*virology | 32 | 55.0 |
Microscopy, Fluorescence | 12 | 0.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Protein Binding | 52 | 0.0 |
T-Lymphocytes/*virology | 12 | 23.0 |
CD8-Positive T-Lymphocytes/*immunology | 8 | 2.0 |
Killer Cells, Natural/immunology | 3 | 0.0 |
Pan troglodytes | 9 | 7.0 |
SIV/*immunology | 3 | 11.0 |
Simian Acquired Immunodeficiency Syndrome/*immunology | 3 | 16.0 |
*Virus Replication/drug effects | 2 | 14.0 |
Antiretroviral Therapy, Highly Active/methods | 2 | 16.0 |
Chemokines/*immunology | 13 | 68.0 |
HIV Infections/drug therapy/*immunology | 3 | 4.0 |
Interferon Type II/immunology | 3 | 3.0 |
Leukocytes, Mononuclear/*immunology | 2 | 1.0 |
Membrane Glycoproteins/*immunology | 2 | 1.0 |
Monocyte Chemoattractant Protein-1/immunology | 2 | 66.0 |
RANTES/analysis | 8 | 61.0 |
RNA, Viral/analysis | 9 | 3.0 |
Receptors, Cell Surface/*immunology | 2 | 2.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Up-Regulation/immunology | 11 | 7.0 |
Antiretroviral Therapy, Highly Active/*methods | 2 | 6.0 |
Interferon Type II/*immunology | 3 | 7.0 |
RNA, Messenger/blood | 2 | 3.0 |
RNA, Viral/blood | 19 | 3.0 |
Receptors, Immunologic/immunology | 5 | 4.0 |
Virus Replication/immunology | 14 | 26.0 |
HIV Envelope Protein gp120/*metabolism | 24 | 15.0 |
HIV Envelope Protein gp41/*metabolism | 2 | 11.0 |
Viral Fusion Proteins/*metabolism | 3 | 25.0 |
HIV Infections/*genetics | 15 | 55.0 |
HIV-1/genetics/metabolism/*physiology | 3 | 42.0 |
Microsatellite Repeats | 4 | 0.0 |
Pedigree | 2 | 0.0 |
T-Lymphocytes/metabolism | 12 | 4.0 |
Tropism | 4 | 30.0 |
Antigens, CD/immunology | 7 | 1.0 |
Recurrence | 4 | 0.0 |
HIV-1/metabolism | 5 | 10.0 |
Receptors, CXCR4/immunology/metabolism | 5 | 50.0 |
T-Lymphocytes/immunology | 22 | 1.0 |
Green Fluorescent Proteins | 9 | 1.0 |
Heterocyclic Compounds/pharmacology | 16 | 64.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Macaca fascicularis | 8 | 2.0 |
Receptors, CXCR4/antagonists & inhibitors/metabolism | 2 | 40.0 |
Receptors, Cytokine/metabolism | 11 | 11.0 |
*Receptors, G-Protein-Coupled | 26 | 10.0 |
Receptors, Peptide/metabolism | 6 | 19.0 |
Receptors, Virus/*metabolism | 12 | 12.0 |
HIV Core Protein p24/biosynthesis | 4 | 8.0 |
HIV-1/isolation & purification/*metabolism | 7 | 43.0 |
Receptors, CXCR4/antagonists & inhibitors | 6 | 54.0 |
*Receptors, Virus | 10 | 41.0 |
Chemokines, CXC/metabolism | 18 | 23.0 |
Chemotaxis/*physiology | 3 | 8.0 |
HIV Envelope Protein gp120/metabolism | 36 | 23.0 |
Lymphocytes/metabolism | 5 | 2.0 |
Receptors, CXCR4/*physiology | 20 | 40.0 |
*Gene Deletion | 13 | 1.0 |
Giant Cells/*physiology | 2 | 28.0 |
HIV Seropositivity | 5 | 3.0 |
HIV-1/isolation & purification/*pathogenicity/*physiology | 2 | 66.0 |
Antigens, CD28/immunology | 6 | 4.0 |
Antigens, CD3/immunology | 10 | 3.0 |
Antigens, CD4/immunology | 9 | 4.0 |
Cell Division | 13 | 0.0 |
HIV-1/*immunology | 35 | 7.0 |
*Immunoconjugates | 4 | 1.0 |
Leukocytes, Mononuclear/cytology/immunology | 3 | 6.0 |
Receptors, CCR5/biosynthesis | 31 | 77.0 |
Receptors, Interleukin-2/biosynthesis | 2 | 1.0 |
*Up-Regulation | 6 | 2.0 |
*Genetic Predisposition to Disease | 10 | 0.0 |
*Mutation | 25 | 0.0 |
Chimeric Proteins/genetics/metabolism | 5 | 5.0 |
HIV Envelope Protein gp120/*chemistry/genetics/*metabolism | 8 | 66.0 |
Gene Products, env/*metabolism | 6 | 21.0 |
Receptors, CCR5 | 35 | 70.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/virology | 3 | 60.0 |
Chemotaxis/*drug effects/immunology | 2 | 100.0 |
Dendritic Cells/cytology/*drug effects/immunology | 3 | 25.0 |
Lymph Nodes/cytology | 2 | 4.0 |
Receptors, CXCR4/biosynthesis | 16 | 48.0 |
Receptors, Chemokine/biosynthesis | 11 | 22.0 |
Cell Lineage | 2 | 0.0 |
Chemotaxis, Leukocyte | 19 | 10.0 |
Clone Cells | 10 | 0.0 |
Cytotoxicity Tests, Immunologic | 3 | 0.0 |
HIV Antigens/*immunology | 5 | 9.0 |
HIV-1/immunology | 7 | 9.0 |
T-Lymphocytes, Cytotoxic/*immunology | 5 | 0.0 |
Postoperative Period | 2 | 0.0 |
Receptors, CCR5/genetics | 45 | 71.0 |
Antibody Specificity | 16 | 1.0 |
Endocytosis | 10 | 2.0 |
HIV-1/physiology | 19 | 21.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Antibodies, Monoclonal/chemistry/immunology | 3 | 27.0 |
Epitopes/chemistry | 2 | 2.0 |
Tyrosine/*metabolism | 5 | 1.0 |
Anti-HIV Agents/*chemical synthesis/pharmacology | 3 | 42.0 |
HIV-1/drug effects | 5 | 12.0 |
Microbial Sensitivity Tests | 8 | 3.0 |
Molecular Conformation | 3 | 1.0 |
HIV-1/isolation & purification/*metabolism/physiology | 5 | 83.0 |
Leukocytes, Mononuclear/metabolism/*virology | 3 | 75.0 |
Giant Cells | 15 | 25.0 |
HIV-1/isolation & purification/metabolism/*physiology | 2 | 66.0 |
Tetradecanoylphorbol Acetate/pharmacology | 10 | 0.0 |
Antiretroviral Therapy, Highly Active | 11 | 3.0 |
Lectins/pharmacology | 2 | 5.0 |
Macrophage Inflammatory Protein-1/*biosynthesis | 4 | 57.0 |
RANTES/*biosynthesis | 4 | 33.0 |
Receptors, CXCR4/*biosynthesis | 10 | 32.0 |
Lymphocyte Activation/immunology | 11 | 2.0 |
Mice, Knockout | 11 | 0.0 |
T-Lymphocyte Subsets/immunology | 4 | 1.0 |
Antibodies, Monoclonal | 12 | 0.0 |
Receptors, Chemokine/*genetics/*metabolism | 3 | 42.0 |
Tissue Distribution | 5 | 0.0 |
Biological Markers/analysis | 9 | 1.0 |
HLA-DR Antigens/metabolism | 2 | 1.0 |
Interferon Type II/pharmacology | 9 | 1.0 |
Transcription, Genetic | 20 | 0.0 |
HIV Infections/*immunology/transmission | 3 | 42.0 |
Immunity, Mucosal | 4 | 5.0 |
Receptors, CCR5/chemistry/*immunology | 5 | 100.0 |
Receptors, HIV/*immunology | 5 | 45.0 |
Cytokines/*immunology | 3 | 3.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
Killer Cells, Natural/*immunology | 4 | 0.0 |
Interferon-alpha/*pharmacology | 3 | 2.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
*Promoter Regions (Genetics) | 9 | 0.0 |
Survival Analysis | 6 | 0.0 |
Thailand | 5 | 3.0 |
Aged, 80 and over | 22 | 0.0 |
Arthritis, Rheumatoid/*immunology/pathology | 3 | 9.0 |
Biopsy | 11 | 0.0 |
Cytokines/biosynthesis/genetics | 4 | 6.0 |
Interleukin-10/biosynthesis/genetics | 2 | 13.0 |
Receptors, CCR5/biosynthesis/genetics | 8 | 88.0 |
Receptors, Chemokine/biosynthesis/genetics | 7 | 38.0 |
CHO Cells | 46 | 2.0 |
Microscopy, Confocal | 11 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Cameroon/epidemiology | 2 | 16.0 |
Genes, Viral | 2 | 0.0 |
Genes, env | 11 | 18.0 |
Genes, gag | 4 | 17.0 |
Genes, pol | 3 | 16.0 |
Giant Cells/virology | 5 | 12.0 |
HIV Infections/epidemiology/*virology | 2 | 25.0 |
HIV-1/classification/*genetics/isolation & purification | 3 | 37.0 |
Receptors, Virus/metabolism | 5 | 8.0 |
Antigens, CD4/analysis/metabolism | 2 | 66.0 |
HIV Core Protein p24/analysis | 9 | 12.0 |
*HIV-1/metabolism | 2 | 100.0 |
Consensus Sequence | 6 | 0.0 |
HIV Infections/transmission/*virology | 5 | 45.0 |
Heterosexuality | 4 | 20.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
*Gene Expression Regulation | 7 | 0.0 |
Polymorphism, Genetic/genetics | 7 | 1.0 |
RNA, Messenger/genetics/metabolism | 18 | 0.0 |
Antigens, CD4/analysis | 7 | 1.0 |
Blood Component Removal | 2 | 4.0 |
Feasibility Studies | 2 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
Antibodies, Monoclonal/metabolism | 15 | 4.0 |
HIV Infections/metabolism | 2 | 14.0 |
HIV-1/genetics/*metabolism/physiology | 2 | 28.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Models, Biological | 23 | 0.0 |
Plasmids/metabolism | 9 | 0.0 |
CD4-Positive T-Lymphocytes/virology | 17 | 25.0 |
Virus Integration | 6 | 9.0 |
Interferon-beta/*administration & dosage | 2 | 28.0 |
Receptors, Cytokine/biosynthesis | 4 | 22.0 |
Liver/pathology | 2 | 1.0 |
Lymphocytes/metabolism/pathology | 2 | 11.0 |
Monocytes/cytology/drug effects/*immunology | 3 | 18.0 |
DNA/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Mutagenesis | 21 | 2.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Antigens, CD3/analysis | 3 | 1.0 |
CD4-Positive T-Lymphocytes/chemistry/immunology | 2 | 20.0 |
Arthritis, Rheumatoid/*metabolism | 2 | 3.0 |
Leukocytes, Mononuclear/chemistry | 2 | 7.0 |
Synovial Membrane/*chemistry | 2 | 28.0 |
Drug Interactions | 6 | 0.0 |
HIV Infections/*immunology/virology | 10 | 15.0 |
Morphine/pharmacology | 4 | 28.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Creatinine/blood | 2 | 0.0 |
Japan | 4 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Prognosis | 14 | 0.0 |
Treatment Outcome | 11 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 18 | 2.0 |
*Lymphocyte Activation | 5 | 0.0 |
Lymphocyte Culture Test, Mixed | 4 | 0.0 |
RNA, Messenger/biosynthesis | 25 | 1.0 |
Receptors, CCR5/*biosynthesis/genetics | 15 | 100.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Adoptive Transfer | 5 | 6.0 |
Antigens, CD/physiology | 4 | 1.0 |
Cell Adhesion | 8 | 0.0 |
*Cell Movement | 2 | 1.0 |
Integrin alpha4 | 2 | 5.0 |
Mice, Inbred C57BL | 14 | 0.0 |
Mice, SCID | 15 | 1.0 |
Cell Line, Transformed | 26 | 1.0 |
Glycosylation | 14 | 1.0 |
Polysaccharides/*metabolism | 3 | 13.0 |
Sulfates/*metabolism | 5 | 15.0 |
Acquired Immunodeficiency Syndrome/immunology | 2 | 2.0 |
HIV Antigens/immunology | 4 | 10.0 |
HIV Core Protein p24/immunology | 3 | 8.0 |
Disease-Free Survival | 4 | 0.0 |
Double-Blind Method | 2 | 0.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 2 | 3.0 |
T-Lymphocyte Subsets/cytology/*immunology | 3 | 12.0 |
Immune Sera/immunology | 2 | 1.0 |
Interleukin-12/*pharmacology | 2 | 4.0 |
Receptors, Antigen, T-Cell/metabolism | 3 | 1.0 |
T-Lymphocytes/drug effects/*immunology | 2 | 1.0 |
HIV Infections/immunology/pathology/*virology | 3 | 50.0 |
Receptors, HIV/immunology | 4 | 40.0 |
Chemokines, CC/*metabolism | 16 | 30.0 |
Chemokines, CXC/*metabolism | 2 | 3.0 |
Leukocytes/*immunology | 2 | 1.0 |
Monocytes/immunology | 10 | 2.0 |
Neutrophils/immunology | 4 | 2.0 |
Receptors, CCR5/genetics/metabolism | 19 | 73.0 |
Receptors, Interleukin-8B/metabolism | 2 | 40.0 |
Synovial Fluid/cytology/immunology | 3 | 15.0 |
Chemotaxis, Leukocyte/genetics/*immunology | 2 | 40.0 |
Dendritic Cells/immunology/pathology | 2 | 10.0 |
*Alleles | 13 | 0.0 |
Predictive Value of Tests | 9 | 0.0 |
Sequence Deletion/*genetics | 3 | 2.0 |
Survival Rate | 7 | 0.0 |
T-Lymphocytes/immunology/pathology | 2 | 3.0 |
Cell Separation | 11 | 1.0 |
Chemotaxis | 17 | 9.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Gene Library | 3 | 0.0 |
Receptors, CCR5/*chemistry/*metabolism | 4 | 100.0 |
B-Lymphocytes/immunology | 5 | 0.0 |
Chimeric Proteins/immunology | 3 | 9.0 |
Clinical Trials | 5 | 0.0 |
Dendritic Cells/immunology | 2 | 1.0 |
Longitudinal Studies | 15 | 1.0 |
Myocardium/metabolism/pathology | 2 | 6.0 |
*Transcription, Genetic | 2 | 0.0 |
HIV Envelope Protein gp120/*chemistry/physiology | 3 | 75.0 |
Receptors, CCR5/*chemistry/physiology | 6 | 100.0 |
Antigens, CD4/*physiology | 13 | 11.0 |
Receptors, CXCR4/physiology | 22 | 47.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Seroepidemiologic Studies | 2 | 1.0 |
Amides/*pharmacology | 2 | 20.0 |
Ammonium Compounds/*pharmacology | 2 | 50.0 |
HIV-1/*drug effects | 22 | 16.0 |
Membrane Fusion/*drug effects | 8 | 27.0 |
T-Lymphocytes/drug effects/virology | 2 | 33.0 |
Viral Envelope Proteins/*physiology | 2 | 11.0 |
HIV-1/genetics/metabolism/*pathogenicity | 6 | 54.0 |
Polymorphism, Restriction Fragment Length | 11 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Promoter Regions (Genetics) | 9 | 0.0 |
Alanine/genetics/metabolism | 3 | 23.0 |
RANTES/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Viral Envelope Proteins/*metabolism | 7 | 16.0 |
*Antiretroviral Therapy, Highly Active | 6 | 1.0 |
*CD4 Lymphocyte Count | 4 | 1.0 |
HIV-1/drug effects/physiology | 5 | 31.0 |
Intestines/immunology | 2 | 16.0 |
L-Selectin/analysis | 2 | 10.0 |
Organ Specificity | 8 | 0.0 |
Antigens, CD4/biosynthesis/genetics | 4 | 44.0 |
Cell Differentiation/drug effects | 11 | 1.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Monocytes/cytology/drug effects | 2 | 5.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Protein Kinase C/metabolism | 3 | 0.0 |
Receptors, CXCR4/biosynthesis/genetics | 5 | 71.0 |
Virus Latency | 2 | 3.0 |
Calcium/physiology | 3 | 1.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Macrophage Inflammatory Protein-1/secretion | 3 | 60.0 |
Monocytes/drug effects | 4 | 7.0 |
Protein Processing, Post-Translational | 11 | 1.0 |
Protein-Tyrosine Kinase/*metabolism | 5 | 0.0 |
Receptors, CXCR4/drug effects/*physiology | 2 | 33.0 |
HIV Infections/complications | 2 | 4.0 |
Immunologic Techniques | 2 | 0.0 |
In Situ Hybridization | 9 | 0.0 |
RNA/metabolism | 2 | 0.0 |
Receptors, Peptide/*physiology | 2 | 22.0 |
Staining and Labeling | 2 | 0.0 |
HIV-1/*metabolism/pathogenicity | 5 | 26.0 |
Haplorhini | 3 | 1.0 |
Polymorphism, Genetic | 41 | 0.0 |
Receptors, CCR5/*genetics/metabolism | 15 | 93.0 |
Receptors, CXCR4/*genetics/metabolism | 3 | 50.0 |
Sequence Analysis, DNA | 18 | 0.0 |
HIV Envelope Protein gp120/*genetics | 5 | 20.0 |
Peptide Fragments/*genetics | 3 | 6.0 |
Acquired Immunodeficiency Syndrome/*immunology | 8 | 3.0 |
Apoptosis | 11 | 0.0 |
Africa/epidemiology | 3 | 12.0 |
*Models, Theoretical | 2 | 3.0 |
Culture Techniques | 3 | 0.0 |
Herpesvirus 6, Human/*physiology | 2 | 20.0 |
Chemotaxis/drug effects | 10 | 10.0 |
HIV-1/*immunology/physiology | 5 | 14.0 |
Membrane Fusion/immunology | 2 | 50.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 5 | 2.0 |
Chemokines/*analysis | 3 | 60.0 |
Chemokines, CXC/analysis | 2 | 40.0 |
Macrophage Inflammatory Protein-1/analysis | 5 | 83.0 |
Monocyte Chemoattractant Protein-1/analysis | 2 | 20.0 |
HIV Envelope Protein gp120/*genetics/metabolism | 4 | 30.0 |
Adjuvants, Immunologic/pharmacology | 2 | 2.0 |
Chemokines, CXC/*physiology | 2 | 5.0 |
Enzyme Activation | 10 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 8 | 0.0 |
Receptors, Chemokine/analysis/biosynthesis | 2 | 100.0 |
Cell Count | 5 | 0.0 |
Statistics, Nonparametric | 12 | 1.0 |
Antigens, CD4/genetics | 4 | 7.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 8 | 2.0 |
HIV Infections/metabolism/*virology | 2 | 33.0 |
HIV-1/genetics | 2 | 3.0 |
Interleukin-4/pharmacology | 9 | 2.0 |
Luciferases/genetics/metabolism | 3 | 1.0 |
Macrophages/drug effects/immunology/metabolism | 2 | 18.0 |
Membrane Glycoproteins/immunology | 2 | 1.0 |
Monocytes/*cytology/drug effects/immunology | 2 | 22.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 9 | 0.0 |
Acquired Immunodeficiency Syndrome/*drug therapy | 2 | 3.0 |
*Piperidines | 3 | 60.0 |
RANTES/antagonists & inhibitors | 5 | 83.0 |
*Gene Dosage | 3 | 3.0 |
HIV/metabolism | 3 | 20.0 |
Receptors, CCR5/analysis/physiology | 4 | 100.0 |
Receptors, CXCR4/analysis/physiology | 2 | 66.0 |
Receptors, Chemokine/physiology | 8 | 30.0 |
HIV-2/*physiology | 7 | 31.0 |
Membrane Fusion | 30 | 22.0 |
Receptors, CCR5/chemistry/*physiology | 4 | 100.0 |
Tyrosine/metabolism | 5 | 0.0 |
Chemokines, CC/*biosynthesis | 6 | 31.0 |
HIV Envelope Protein gp120/*pharmacology | 4 | 9.0 |
Macrophages/*metabolism | 7 | 2.0 |
Receptors, HIV/*physiology | 21 | 56.0 |
Species Specificity | 15 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 6 | 1.0 |
Cell Polarity | 3 | 2.0 |
DNA, Viral/blood | 3 | 3.0 |
Dimerization | 14 | 0.0 |
Gene Deletion | 19 | 0.0 |
Precipitin Tests | 11 | 0.0 |
Receptors, CCR5/*genetics/*metabolism | 7 | 100.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 3 | 1.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Antigens, CD/*metabolism | 3 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 3 | 2.0 |
Biological Markers | 8 | 0.0 |
Cervix Uteri/immunology | 2 | 25.0 |
Flow Cytometry/methods | 5 | 1.0 |
Receptors, Interleukin-2/*metabolism | 2 | 2.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
HIV Infections/*genetics/immunology | 8 | 50.0 |
HIV Seronegativity/*genetics/immunology | 2 | 100.0 |
Immunity, Natural | 16 | 7.0 |
Anti-HIV Agents/pharmacology/*therapeutic use | 3 | 9.0 |
Receptors, CXCR4/*antagonists & inhibitors | 10 | 37.0 |
Acquired Immunodeficiency Syndrome/*immunology/virology | 2 | 28.0 |
Brain/*virology | 5 | 41.0 |
Lymphoid Tissue/*virology | 3 | 42.0 |
AIDS-Related Opportunistic Infections/complications/*virology | 2 | 50.0 |
Monocytes/metabolism | 8 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
Phytohemagglutinins/pharmacology | 8 | 1.0 |
Chemokines, CXC/pharmacology | 16 | 22.0 |
AIDS-Related Opportunistic Infections/*immunology | 2 | 6.0 |
CD4-Positive T-Lymphocytes/*immunology/*virology | 2 | 13.0 |
HIV/immunology/*physiology | 2 | 10.0 |
HIV Infections/*immunology | 28 | 6.0 |
Muromonab-CD3/immunology | 2 | 20.0 |
*Drug Design | 2 | 2.0 |
Enzyme Inhibitors/pharmacology | 11 | 0.0 |
HIV/drug effects/physiology | 2 | 16.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Arthritis, Rheumatoid/*genetics | 2 | 2.0 |
Follow-Up Studies | 11 | 0.0 |
Inhibitory Concentration 50 | 11 | 3.0 |
Neutrophils/drug effects/virology | 2 | 100.0 |
Piperidines/chemistry | 2 | 50.0 |
CD4-Positive T-Lymphocytes/immunology/*metabolism | 5 | 14.0 |
HIV Long-Term Survivors | 7 | 41.0 |
CD4-Positive T-Lymphocytes/*virology | 12 | 14.0 |
HIV Infections/prevention & control/virology | 2 | 100.0 |
Culture Media, Conditioned | 3 | 0.0 |
Protein Processing, Post-Translational/drug effects | 3 | 2.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
HIV-1 Reverse Transcriptase/metabolism | 4 | 44.0 |
Membrane Proteins/biosynthesis/genetics | 2 | 5.0 |
Proteins/metabolism | 2 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Antigens, CD/metabolism | 8 | 0.0 |
Chemotaxis/physiology | 5 | 15.0 |
Culture Media, Serum-Free | 4 | 1.0 |
*Protein-Serine-Threonine Kinases | 4 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
*Genome, Viral | 4 | 5.0 |
Virulence/genetics | 2 | 2.0 |
Receptors, CXCR4/chemistry/*immunology | 2 | 66.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 2 | 4.0 |
Cell Movement/*physiology | 3 | 1.0 |
Chemokines, CXC/physiology | 2 | 9.0 |
Inflammation/metabolism | 4 | 5.0 |
Lymphocyte Subsets/cytology | 2 | 11.0 |
Macrophage Inflammatory Protein-1/physiology | 3 | 60.0 |
RANTES/physiology | 4 | 57.0 |
Receptors, CCR5/drug effects/physiology | 2 | 100.0 |
Biological Assay | 3 | 1.0 |
Chemokines/antagonists & inhibitors/metabolism | 2 | 50.0 |
HIV-1/metabolism/*physiology | 7 | 41.0 |
Microglia/cytology/metabolism/virology | 2 | 100.0 |
Recombination, Genetic | 11 | 1.0 |
HIV Infections/therapy | 3 | 20.0 |
Receptors, CCR5/*blood/*genetics | 2 | 100.0 |
Reproducibility of Results | 3 | 0.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Actins/metabolism | 6 | 1.0 |
DNA, Viral/isolation & purification | 2 | 8.0 |
RNA, Viral/isolation & purification | 2 | 15.0 |
Receptors, CXCR4/genetics/metabolism | 12 | 48.0 |
Cell Cycle | 3 | 0.0 |
DNA/analysis | 3 | 0.0 |
Cell Compartmentation | 5 | 1.0 |
Cell Membrane/*metabolism | 3 | 1.0 |
Chemokines, CC | 2 | 66.0 |
Golgi Apparatus/metabolism | 3 | 1.0 |
Protein Transport | 4 | 0.0 |
European Continental Ancestry Group | 6 | 0.0 |
Risk-Taking | 3 | 11.0 |
Sexual Behavior | 4 | 5.0 |
Thymus Gland/cytology/metabolism | 3 | 20.0 |
Cercopithecus aethiops | 16 | 1.0 |
*Evolution, Molecular | 12 | 2.0 |
Vero Cells | 2 | 0.0 |
Xenopus laevis | 3 | 0.0 |
Proportional Hazards Models | 8 | 1.0 |
Chemokines, CXC/metabolism/pharmacology | 2 | 25.0 |
HIV Envelope Protein gp120/*toxicity | 2 | 40.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Chemotaxis, Leukocyte/drug effects | 9 | 10.0 |
Endocytosis/drug effects | 2 | 3.0 |
Receptors, CCR5/antagonists & inhibitors/metabolism | 3 | 100.0 |
Antigens, CD4/drug effects/metabolism | 3 | 37.0 |
HIV-1/*pathogenicity | 23 | 25.0 |
Interleukin-10/pharmacology | 5 | 7.0 |
Langerhans Cells/metabolism/*virology | 2 | 100.0 |
Receptors, CCR5/drug effects/metabolism | 3 | 75.0 |
Receptors, CXCR4/drug effects/*metabolism | 2 | 40.0 |
Receptors, HIV/drug effects/*metabolism | 4 | 100.0 |
T-Lymphocytes/virology | 20 | 29.0 |
Thymus Gland/cytology | 3 | 3.0 |
Macrophage Inflammatory Protein-1/genetics/metabolism | 4 | 80.0 |
Mice, Transgenic | 5 | 0.0 |
Monocyte Chemoattractant Protein-1/genetics/metabolism | 3 | 30.0 |
Receptors, Chemokine/genetics/metabolism | 8 | 34.0 |
HIV-1/genetics/*immunology | 5 | 7.0 |
Linkage (Genetics) | 3 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
HIV Long Terminal Repeat/physiology | 2 | 33.0 |
*Membrane Glycoproteins | 10 | 1.0 |
Viral Envelope Proteins/genetics/metabolism | 4 | 28.0 |
Viral Proteins/genetics/metabolism | 2 | 5.0 |
Dendritic Cells/metabolism | 3 | 6.0 |
Receptors, Chemokine/genetics/metabolism/*physiology | 2 | 33.0 |
Binding, Competitive/immunology | 5 | 5.0 |
Dose-Response Relationship, Immunologic | 7 | 1.0 |
Epitopes/immunology | 6 | 1.0 |
Signal Transduction/immunology | 11 | 3.0 |
SIV/genetics/*pathogenicity | 3 | 37.0 |
Viral Envelope Proteins/*chemistry/genetics/*metabolism | 2 | 66.0 |
Fetal Blood | 2 | 1.0 |
Interleukin-10/*metabolism | 2 | 6.0 |
Monocytes/*metabolism | 2 | 0.0 |
Receptors, IgG/*metabolism | 2 | 3.0 |
Chemokines/*genetics | 5 | 22.0 |
Chemokines, CXC/genetics | 10 | 58.0 |
HIV Infections/genetics/*immunology | 4 | 33.0 |
HIV Seronegativity/*genetics | 3 | 100.0 |
HIV Seropositivity/genetics | 2 | 40.0 |
Immunity, Natural/genetics | 10 | 15.0 |
Antigens, CD40/*immunology | 2 | 5.0 |
Cell Differentiation/*immunology | 2 | 7.0 |
Chemokines, CC/immunology | 3 | 20.0 |
Endocytosis/immunology | 2 | 9.0 |
HIV/*immunology | 4 | 3.0 |
Monocytes/cytology/*immunology | 2 | 5.0 |
Anti-HIV Agents/therapeutic use | 4 | 1.0 |
Receptors, Chemokine/*immunology | 14 | 50.0 |
Virus Replication/*immunology | 6 | 19.0 |
Chemokines/physiology | 7 | 26.0 |
*Endocytosis | 3 | 1.0 |
HIV Long Terminal Repeat | 7 | 5.0 |
Microscopy, Electron | 5 | 0.0 |
Calcium Signaling/immunology | 2 | 9.0 |
HIV Infections/immunology | 9 | 10.0 |
Receptors, Chemokine/*metabolism/physiology | 2 | 33.0 |
Antibodies, Monoclonal/pharmacology | 8 | 1.0 |
Cytopathogenic Effect, Viral | 14 | 9.0 |
Receptors, CXCR4/immunology | 3 | 50.0 |
U937 Cells | 10 | 2.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
DNA Mutational Analysis | 6 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
HIV Infections/*immunology/metabolism | 4 | 33.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
RANTES/*genetics | 8 | 57.0 |
Chemokines/genetics/*metabolism | 4 | 30.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
HIV-1/*genetics/isolation & purification/*physiology | 2 | 66.0 |
Receptors, CXCR4/genetics/*metabolism | 12 | 25.0 |
Sequence Analysis | 2 | 0.0 |
Virus Replication/genetics | 4 | 8.0 |
Receptors, CCR5/metabolism/*physiology | 3 | 75.0 |
Receptors, CXCR4/metabolism/*physiology | 3 | 60.0 |
Drug Resistance, Multiple | 3 | 1.0 |
Molecular Weight | 3 | 0.0 |
Receptors, CCR5/*antagonists & inhibitors/metabolism | 6 | 100.0 |
Analysis of Variance | 5 | 0.0 |
Macrophages/pathology | 3 | 2.0 |
Monocytes/pathology | 2 | 5.0 |
RANTES/*analysis | 2 | 33.0 |
Statistics | 2 | 0.0 |
T-Lymphocytes/pathology | 3 | 2.0 |
Eosinophils/immunology | 2 | 3.0 |
K562 Cells | 2 | 0.0 |
Calcium | 2 | 7.0 |
Receptors, HIV/physiology | 6 | 37.0 |
Immunologic Memory/*immunology | 2 | 6.0 |
Interferon Type II/*biosynthesis | 3 | 1.0 |
Interleukin-2/*biosynthesis | 2 | 1.0 |
Th2 Cells/*immunology | 10 | 7.0 |
*Asian Continental Ancestry Group | 2 | 3.0 |
HIV Seronegativity/*immunology | 4 | 12.0 |
Macrophage Inflammatory Protein-1/blood | 3 | 33.0 |
RANTES/blood | 3 | 27.0 |
Taiwan | 3 | 1.0 |
Immunization | 6 | 1.0 |
Gene Products, gag/immunology | 2 | 6.0 |
Prostitution | 3 | 16.0 |
HIV-1/genetics/*metabolism | 6 | 8.0 |
HIV-1/drug effects/*metabolism | 2 | 100.0 |
Recombinant Proteins/chemistry/metabolism/pharmacology | 2 | 11.0 |
Leukocytes, Mononuclear/immunology/metabolism | 4 | 9.0 |
HIV Envelope Protein gp120/immunology/metabolism | 2 | 13.0 |
Receptors, CXCR4/immunology/*physiology | 2 | 100.0 |
ADP-ribosyl Cyclase | 3 | 0.0 |
*Antigens, CD | 5 | 0.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
Disease Susceptibility | 13 | 1.0 |
HLA-DR Antigens/analysis | 7 | 1.0 |
NAD+ Nucleosidase/analysis | 2 | 4.0 |
Antigens, CD4/analysis/genetics | 2 | 18.0 |
DNA, Viral/analysis | 16 | 4.0 |
Dendritic Cells/immunology/*virology | 2 | 20.0 |
HIV-1/genetics/*isolation & purification | 2 | 4.0 |
Proviruses/isolation & purification | 2 | 11.0 |
Receptors, CCR5/analysis/genetics | 3 | 75.0 |
Receptors, CXCR4/analysis/genetics | 3 | 100.0 |
Leukocytes, Mononuclear/*immunology/virology | 2 | 50.0 |
Receptors, CXCR4/analysis | 18 | 51.0 |
HIV Infections/*drug therapy/*immunology/virology | 2 | 6.0 |
Chimeric Proteins/metabolism | 4 | 2.0 |
Models, Statistical | 5 | 2.0 |
Chemokines/*pharmacology | 5 | 18.0 |
Chemokines, CXC/*pharmacology | 3 | 9.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Peptide Fragments/pharmacology | 7 | 3.0 |
Zidovudine/pharmacology | 4 | 7.0 |
*HIV-1/pathogenicity | 4 | 33.0 |
HIV-1/*genetics/pathogenicity | 5 | 38.0 |
Simian Acquired Immunodeficiency Syndrome/virology | 2 | 25.0 |
England | 2 | 1.0 |
HIV Envelope Protein gp120/*chemistry | 2 | 12.0 |
SIV/*immunology/physiology | 2 | 50.0 |
T-Lymphocytes/immunology/virology | 5 | 27.0 |
Viral Proteins/*physiology | 2 | 6.0 |
Half-Life | 2 | 0.0 |
Hydrolysis | 2 | 0.0 |
SIV/*genetics/pathogenicity | 2 | 40.0 |
Chromosome Mapping | 9 | 0.0 |
*Chromosomes, Human, Pair 3 | 5 | 1.0 |
Finland | 2 | 0.0 |
Genetic Screening | 3 | 0.0 |
Retrospective Studies | 10 | 0.0 |
Anti-HIV Agents/*pharmacology/therapeutic use | 5 | 20.0 |
Receptors, CCR5/*drug effects | 3 | 100.0 |
RANTES/biosynthesis | 7 | 41.0 |
RNA, Messenger | 4 | 0.0 |
*Antigens, Protozoan | 2 | 10.0 |
*Gene Expression | 3 | 0.0 |
*Protozoan Proteins | 2 | 5.0 |
Receptors, CCR5/*genetics/physiology | 5 | 83.0 |
Antigens, CD4/*analysis | 4 | 2.0 |
Bone Marrow Cells/cytology/metabolism | 2 | 10.0 |
Apoptosis/*physiology | 3 | 0.0 |
Caspases/metabolism | 3 | 0.0 |
Receptors, Cytokine/analysis | 2 | 13.0 |
Naphthoquinones/*pharmacology | 2 | 9.0 |
Macrophages/immunology/metabolism | 4 | 8.0 |
Epitopes | 6 | 0.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Models, Chemical | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Dendritic Cells/*physiology/virology | 2 | 100.0 |
Receptors, Formyl Peptide | 4 | 5.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
HIV Envelope Protein gp120/genetics/*metabolism | 14 | 37.0 |
Immunoglobulin G/metabolism | 2 | 1.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Peptide Fragments/chemistry/genetics/*metabolism | 5 | 38.0 |
DNA/genetics | 5 | 0.0 |
Family Health | 2 | 0.0 |
Inflammatory Bowel Diseases/*genetics | 3 | 12.0 |
SIV/*pathogenicity | 6 | 37.0 |
Virion | 2 | 8.0 |
Monocyte Chemoattractant Protein-1/immunology/metabolism | 2 | 100.0 |
Monocytes/immunology/metabolism | 4 | 8.0 |
RANTES/immunology/metabolism | 2 | 50.0 |
Receptors, Chemokine/*biosynthesis/immunology | 3 | 60.0 |
Synovial Fluid/cytology/immunology/*metabolism | 2 | 50.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Chemokines/biosynthesis | 4 | 10.0 |
Membrane Glycoproteins/biosynthesis | 6 | 3.0 |
Periodontitis/*immunology | 2 | 11.0 |
T-Lymphocyte Subsets/*metabolism | 2 | 6.0 |
Th1 Cells/*metabolism | 4 | 14.0 |
HIV Infections/*genetics/immunology/virology | 3 | 75.0 |
RANTES/analysis/*biosynthesis | 2 | 100.0 |
Receptors, CCR5/biosynthesis/*genetics | 4 | 100.0 |
Receptors, HIV/genetics | 4 | 40.0 |
Antigen Presentation | 2 | 0.0 |
*Bacterial Toxins | 3 | 2.0 |
Biological Markers/blood | 5 | 0.0 |
Cell Division/immunology | 4 | 1.0 |
Enterotoxins/immunology | 3 | 5.0 |
Epitopes, T-Lymphocyte/immunology | 3 | 3.0 |
Models, Immunological | 2 | 0.0 |
Staphylococcus aureus/immunology | 3 | 2.0 |
Antigens, CD/*biosynthesis | 3 | 1.0 |
Antigens, CD40/biosynthesis | 2 | 7.0 |
Antigens, CD80/biosynthesis | 2 | 3.0 |
Cell Differentiation/immunology | 20 | 6.0 |
Chemokines/*biosynthesis | 9 | 30.0 |
HLA-DR Antigens/biosynthesis | 3 | 3.0 |
Integrins/biosynthesis | 2 | 8.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 2 | 2.0 |
Antiviral Agents/pharmacology | 4 | 6.0 |
Osteosarcoma | 3 | 3.0 |
Chondroitin Sulfates/pharmacology | 2 | 16.0 |
Glycosaminoglycans/metabolism | 2 | 4.0 |
Heparin/pharmacology | 3 | 1.0 |
*Antigens, Differentiation | 2 | 2.0 |
Cell Adhesion Molecules/*metabolism | 6 | 2.0 |
Exons | 3 | 0.0 |
Hematopoietic Stem Cells/cytology/*immunology | 2 | 4.0 |
Placenta/cytology/immunology | 2 | 66.0 |
Protein Biosynthesis | 4 | 0.0 |
Acquired Immunodeficiency Syndrome/transmission | 2 | 33.0 |
Interferon-gamma, Recombinant/pharmacology | 3 | 1.0 |
Europe | 4 | 1.0 |
Receptors, CCR5/classification/*genetics | 4 | 80.0 |
Age of Onset | 4 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 2 | 0.0 |
Odds Ratio | 7 | 0.0 |
Africa | 2 | 2.0 |
Asia | 2 | 2.0 |
Interleukin-2/immunology/*pharmacology | 2 | 28.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Calcium Signaling/drug effects/physiology | 2 | 8.0 |
HIV-1/metabolism/*pathogenicity | 10 | 55.0 |
Antigens, CD4/chemistry/*metabolism | 3 | 11.0 |
HIV Envelope Protein gp120/chemistry/genetics/*metabolism | 6 | 75.0 |
Protein Binding/genetics | 4 | 1.0 |
Solubility | 8 | 0.0 |
Cysteine/physiology | 2 | 22.0 |
GTP-Binding Protein alpha Subunits, Gi-Go/metabolism | 3 | 8.0 |
*Signal Transduction | 12 | 0.0 |
HIV Infections/immunology/*metabolism | 2 | 28.0 |
Macrophages/drug effects/metabolism | 2 | 4.0 |
Cell Proliferation | 2 | 1.0 |
Cost of Illness | 2 | 8.0 |
HIV Antibodies/blood | 7 | 9.0 |
HIV Envelope Protein gp120/immunology | 7 | 8.0 |
HIV Envelope Protein gp41/immunology | 2 | 9.0 |
HIV Seronegativity/genetics/*immunology | 2 | 100.0 |
Immunoglobulin A/blood | 2 | 1.0 |
Immunoglobulin G/blood | 5 | 1.0 |
Interferon Type II/genetics | 4 | 5.0 |
Interleukin-4/genetics | 3 | 7.0 |
Intestines/*immunology | 2 | 11.0 |
Macrophage Inflammatory Protein-1/genetics | 6 | 46.0 |
*HIV Long-Term Survivors | 4 | 21.0 |
Receptors, G-Protein-Coupled/metabolism | 2 | 11.0 |
Viremia/*virology | 4 | 25.0 |
Cell Survival | 4 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Receptors, CCR5/*genetics/immunology | 6 | 100.0 |
Thermodynamics | 3 | 0.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
RNA, Viral/genetics | 2 | 2.0 |
Colitis, Ulcerative/immunology | 2 | 14.0 |
Intestinal Mucosa/immunology | 3 | 5.0 |
Neurons/*metabolism | 3 | 1.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Antigens, CD4/biosynthesis | 9 | 10.0 |
Genes, nef/genetics | 2 | 33.0 |
Genetic Vectors | 15 | 0.0 |
HIV-1/*drug effects/genetics/physiology | 4 | 19.0 |
Polymorphism, Genetic/*genetics | 10 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Gene Frequency/genetics | 4 | 0.0 |
Point Mutation | 9 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Ethnic Groups/genetics | 4 | 2.0 |
Macrophage Inflammatory Protein-1/*genetics | 2 | 40.0 |
Chemokines, CC/genetics/*metabolism | 4 | 28.0 |
Lipopolysaccharides/pharmacology | 13 | 1.0 |
Monocytes/drug effects/metabolism | 4 | 4.0 |
Macrophage Inflammatory Protein-1/biosynthesis/genetics | 3 | 75.0 |
Monocyte Chemoattractant Protein-1/biosynthesis/genetics | 2 | 18.0 |
RANTES/biosynthesis/genetics | 4 | 66.0 |
Transcription, Genetic/immunology | 2 | 2.0 |
Spleen/virology | 2 | 33.0 |
Interleukin-10/*pharmacology | 5 | 5.0 |
Pregnancy Complications, Infectious | 2 | 11.0 |
*Homozygote | 2 | 1.0 |
Mutation/genetics | 7 | 0.0 |
*Chemokines, CC | 8 | 10.0 |
RANTES/*analogs & derivatives/*pharmacology | 3 | 100.0 |
Astrocytes/metabolism/pathology | 2 | 7.0 |
Microglia/metabolism/pathology | 2 | 25.0 |
Neurons/*metabolism/pathology | 2 | 3.0 |
Chemokines, CC/*analysis | 2 | 33.0 |
Cell Membrane/immunology/metabolism | 4 | 3.0 |
Down-Regulation/*immunology | 3 | 5.0 |
T-Lymphocytes/immunology/metabolism | 5 | 4.0 |
HIV-1/*drug effects/metabolism/physiology | 2 | 20.0 |
RANTES/immunology | 5 | 83.0 |
DNA, Viral/biosynthesis | 5 | 9.0 |
RANTES/*biosynthesis/immunology | 2 | 100.0 |
Receptors, CCR5/*biosynthesis/immunology | 6 | 100.0 |
Chemokines, CC/metabolism/pharmacology | 2 | 12.0 |
Ethiopia | 3 | 11.0 |
*Prostitution | 4 | 23.0 |
Gene Therapy/*methods | 3 | 0.0 |
HIV Infections/*therapy | 2 | 6.0 |
Receptors, CCR5/antagonists & inhibitors/*genetics | 3 | 100.0 |
Transduction, Genetic | 5 | 1.0 |
GTP-Binding Proteins/metabolism | 11 | 4.0 |
Monocyte Chemoattractant Proteins/pharmacology | 4 | 36.0 |
Receptors, Chemokine/chemistry | 2 | 66.0 |
Rhodopsin/chemistry | 2 | 28.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
RANTES/*immunology/pharmacology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/immunology/*virology | 3 | 13.0 |
Chimera | 5 | 2.0 |
Anti-Inflammatory Agents, Non-Steroidal/pharmacology | 2 | 2.0 |
Monocyte Chemoattractant Protein-1/pharmacology | 6 | 28.0 |
Receptors, CCR5/*biosynthesis/genetics/physiology | 2 | 100.0 |
Receptors, CCR5/immunology/metabolism | 9 | 81.0 |
Receptors, Chemokine/immunology/metabolism | 4 | 66.0 |
*Viral Load | 7 | 4.0 |
Antigens, CD4/genetics/*metabolism | 6 | 12.0 |
HIV Antibodies/immunology | 7 | 11.0 |
HIV-1/*metabolism/physiology | 5 | 38.0 |
Microscopy, Immunoelectron | 4 | 0.0 |
Adaptation, Biological | 3 | 23.0 |
Microglia/metabolism/*virology | 4 | 80.0 |
Receptors, CCR5/*agonists | 2 | 100.0 |
Receptors, Chemokine/*antagonists & inhibitors | 7 | 41.0 |
HIV-1/*chemistry | 2 | 6.0 |
Receptors, CCR5/*chemistry | 3 | 75.0 |
Monocytes/drug effects/immunology | 2 | 5.0 |
Phosphorylation/drug effects | 3 | 0.0 |
RANTES/genetics/metabolism | 3 | 50.0 |
Receptors, CCR5/chemistry/genetics/*metabolism | 11 | 91.0 |
Integrin alpha4/analysis | 2 | 66.0 |
HIV Infections/etiology/immunology/virology | 2 | 50.0 |
Inflammation/immunology/pathology | 3 | 18.0 |
Gene Targeting | 3 | 0.0 |
Genetic Engineering | 2 | 2.0 |
HIV Infections/metabolism/*prevention & control | 2 | 100.0 |
Macrophages/metabolism/virology | 5 | 62.0 |
Transgenes | 2 | 0.0 |
Receptors, Chemokine/immunology/*metabolism | 3 | 30.0 |
Remission, Spontaneous | 2 | 2.0 |
Th1 Cells/*immunology/metabolism | 2 | 9.0 |
Th2 Cells/*immunology/metabolism | 2 | 7.0 |
Biological Transport | 4 | 0.0 |
3T3 Cells | 20 | 0.0 |
*Cell Fusion | 5 | 13.0 |
HIV Core Protein p24/metabolism | 8 | 20.0 |
*Virus Assembly | 2 | 8.0 |
Injections, Intradermal | 3 | 6.0 |
Injections, Intravenous | 2 | 0.0 |
Pilot Projects | 3 | 0.0 |
Receptors, Lymphocyte Homing/biosynthesis | 2 | 11.0 |
*Bacterial Proteins | 2 | 1.0 |
Immunity, Cellular | 10 | 1.0 |
Lymphocyte Subsets/pathology | 2 | 8.0 |
Lymph Nodes/metabolism/pathology | 3 | 12.0 |
Fluorescent Antibody Technique, Direct | 3 | 2.0 |
HIV Infections/*transmission | 6 | 10.0 |
Graft Rejection/*immunology | 6 | 7.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Membrane Proteins/metabolism | 6 | 1.0 |
HIV Infections/blood/immunology/*virology | 2 | 25.0 |
Leukocytes, Mononuclear/immunology/*virology | 3 | 33.0 |
Receptors, CCR5/biosynthesis/*metabolism | 3 | 100.0 |
Receptors, CXCR4/biosynthesis/*metabolism | 2 | 50.0 |
Combinatorial Chemistry Techniques | 2 | 10.0 |
Receptors, CCR5/*antagonists & inhibitors/genetics/metabolism | 5 | 83.0 |
HIV Infections/blood | 2 | 18.0 |
Arthritis, Rheumatoid/immunology | 3 | 3.0 |
Asthma/immunology | 2 | 5.0 |
DNA Primers/genetics | 16 | 1.0 |
HIV-1/metabolism/pathogenicity | 2 | 66.0 |
Severity of Illness Index | 3 | 0.0 |
*Gene Frequency | 5 | 0.0 |
HIV-1/*genetics/immunology | 2 | 8.0 |
HIV Infections/blood/immunology | 2 | 25.0 |
Macrophage-1 Antigen/*physiology | 2 | 10.0 |
Macrophages/*immunology/virology | 2 | 28.0 |
Monocytes/*immunology/metabolism/virology | 2 | 66.0 |
Immunoglobulin G/*blood | 2 | 3.0 |
Age Factors | 3 | 0.0 |
Linkage Disequilibrium | 5 | 0.0 |
Perinatal Care | 2 | 22.0 |
HIV-1/drug effects/genetics/*immunology | 2 | 50.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Receptors, CCR5/*biosynthesis/genetics/immunology | 2 | 100.0 |
CD4-Positive T-Lymphocytes/*metabolism | 12 | 13.0 |
HIV Seronegativity/immunology | 3 | 5.0 |
Mycobacterium tuberculosis/*immunology | 3 | 4.0 |
Isoantigens/immunology | 3 | 3.0 |
Gene Products, env/genetics/metabolism | 5 | 35.0 |
Receptors, Cytokine/*metabolism | 13 | 15.0 |
CD4-Positive T-Lymphocytes/physiology/*virology | 2 | 40.0 |
HIV Envelope Protein gp120/pharmacology | 4 | 18.0 |
Alzheimer Disease/*genetics | 3 | 0.0 |
Apolipoproteins E/genetics | 3 | 0.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
Antibodies, Viral/blood | 2 | 1.0 |
Interferon Type II/biosynthesis | 3 | 0.0 |
Chemokines/pharmacology | 16 | 48.0 |
Binding Sites/genetics | 5 | 0.0 |
Chemokines/genetics/metabolism | 2 | 18.0 |
Conserved Sequence | 5 | 0.0 |
Databases, Factual | 3 | 1.0 |
HIV/genetics/*metabolism | 2 | 66.0 |
HIV Envelope Protein gp120/genetics/metabolism | 5 | 62.0 |
Peptide Fragments/genetics/metabolism | 3 | 2.0 |
SIV/genetics/*metabolism | 2 | 33.0 |
Amides/pharmacology | 6 | 11.0 |
Ammonium Compounds/pharmacology | 6 | 26.0 |
Antibodies, Viral/*immunology | 2 | 4.0 |
*Genes, Reporter | 2 | 4.0 |
T-Lymphocytes/cytology/*virology | 2 | 40.0 |
DNA, Viral | 12 | 7.0 |
Leukocytes, Mononuclear/cytology/virology | 4 | 33.0 |
RANTES/metabolism/pharmacology | 4 | 50.0 |
Receptors, CCR5/*antagonists & inhibitors/biosynthesis | 3 | 100.0 |
Receptors, CXCR4/*antagonists & inhibitors/biosynthesis | 2 | 100.0 |
Genome, Viral | 4 | 3.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 6 | 8.0 |
CD8-Positive T-Lymphocytes/immunology/metabolism | 4 | 9.0 |
T-Lymphocyte Subsets/*immunology/*metabolism | 3 | 11.0 |
Th2 Cells/immunology/metabolism | 4 | 10.0 |
Lymphocyte Depletion | 3 | 1.0 |
Monocytes/*immunology/metabolism | 2 | 5.0 |
RANTES/genetics/immunology | 2 | 100.0 |
Chemotaxis, Leukocyte/*drug effects | 4 | 6.0 |
Endothelium, Vascular/cytology | 3 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
Receptors, CCR5/genetics/*physiology | 7 | 100.0 |
HIV Envelope Protein gp120/genetics/immunology | 2 | 13.0 |
HIV-1/*immunology/*pathogenicity | 3 | 33.0 |
Ribonucleases/metabolism | 3 | 2.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Lod Score | 3 | 0.0 |
Hybrid Cells | 6 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Inflammation/immunology | 2 | 1.0 |
HIV-1/*growth & development/immunology | 2 | 40.0 |
Proviruses/*isolation & purification | 2 | 22.0 |
Cell Culture Techniques | 2 | 0.0 |
Chemokines, CXC/genetics/pharmacology | 2 | 100.0 |
Interleukin-2/pharmacology | 6 | 1.0 |
RNA, Messenger/drug effects/metabolism | 4 | 2.0 |
Antigens, CD4/physiology | 18 | 22.0 |
HIV-1/drug effects/*physiology | 9 | 22.0 |
Kidney | 9 | 2.0 |
Luciferases/genetics | 5 | 1.0 |
Antigens, CD34/analysis | 3 | 0.0 |
Chemokines/*biosynthesis/genetics | 4 | 28.0 |
Fetal Blood/*cytology | 2 | 1.0 |
Hematopoietic Stem Cells/immunology/*virology | 2 | 66.0 |
Th1 Cells/immunology/metabolism | 3 | 7.0 |
Chemokines/blood | 2 | 20.0 |
Crohn Disease/genetics | 2 | 13.0 |
*Apoptosis | 6 | 0.0 |
Acquired Immunodeficiency Syndrome/genetics/*immunology/virology | 2 | 100.0 |
HIV Infections/genetics/*immunology/virology | 4 | 80.0 |
Signal Transduction/physiology | 4 | 0.0 |
Chemokines/immunology | 3 | 18.0 |
Gene Products, env/chemistry/genetics | 2 | 66.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Terminology | 2 | 1.0 |
Continental Population Groups/genetics | 4 | 4.0 |
Binding Sites, Antibody | 5 | 1.0 |
CD8-Positive T-Lymphocytes/metabolism | 8 | 10.0 |
Cell Lineage/immunology | 2 | 6.0 |
Cell Migration Inhibition | 5 | 4.0 |
T-Lymphocyte Subsets/cytology/immunology/*metabolism | 2 | 40.0 |
Anti-HIV Agents/metabolism | 2 | 66.0 |
Acquired Immunodeficiency Syndrome/*virology | 7 | 35.0 |
HIV-1/pathogenicity/*physiology | 10 | 37.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 3 | 4.0 |
Antibody Formation | 4 | 0.0 |
HIV-1/*genetics/*immunology | 2 | 25.0 |
Immune Tolerance | 2 | 0.0 |
Lymph Nodes/virology | 4 | 26.0 |
Survivors | 3 | 3.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 5 | 0.0 |
Receptors, Virus/*physiology | 4 | 10.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Receptors, CXCR4/*biosynthesis/genetics | 3 | 27.0 |
Receptors, IgG/metabolism | 3 | 4.0 |
Peptide Fragments/*genetics/metabolism | 3 | 23.0 |
Multiple Sclerosis/drug therapy/immunology | 2 | 66.0 |
T-Lymphocytes/physiology | 4 | 3.0 |
Cytokines/metabolism | 4 | 0.0 |
Receptors, Chemokine/genetics/immunology | 2 | 66.0 |
ADP-ribosyl Cyclase/analysis | 2 | 9.0 |
Apoptosis/drug effects | 3 | 0.0 |
Cytokines/analysis | 2 | 2.0 |
Drug Resistance, Viral | 4 | 7.0 |
HIV-1/*drug effects/metabolism | 2 | 14.0 |
Leukocytes, Mononuclear | 2 | 4.0 |
Anti-HIV Agents/chemistry/*pharmacology | 3 | 15.0 |
Receptors, Chemokine/genetics/*immunology | 5 | 50.0 |
Antigens, CD3/metabolism | 6 | 3.0 |
Kidney Tubules/metabolism/pathology | 2 | 28.0 |
Monocyte Chemoattractant Protein-1/*metabolism | 3 | 9.0 |
Receptors, Virus/physiology | 3 | 12.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
Receptors, Virus/*genetics | 3 | 16.0 |
Algorithms | 2 | 0.0 |
Cluster Analysis | 2 | 1.0 |
Up-Regulation/genetics/immunology | 2 | 3.0 |
Antigens, CD4/metabolism/*physiology | 2 | 50.0 |
Chemokines, CXC/antagonists & inhibitors/physiology | 2 | 66.0 |
Enzyme Activation/immunology | 3 | 2.0 |
src Homology Domains/immunology | 2 | 7.0 |
Endopeptidases/metabolism | 3 | 2.0 |
Receptors, Chemokine/*agonists | 2 | 40.0 |
*Genes, env | 5 | 16.0 |
HIV-1/classification/genetics/*physiology | 3 | 60.0 |
*Phylogeny | 4 | 2.0 |
CD4-Positive T-Lymphocytes/immunology/virology | 5 | 17.0 |
Asthma/*genetics | 2 | 3.0 |
Family | 3 | 0.0 |
Great Britain | 2 | 0.0 |
Macrophages/immunology/virology | 3 | 33.0 |
Chemokines, CXC/biosynthesis/genetics | 2 | 25.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
RNA, Neoplasm/biosynthesis/genetics | 2 | 3.0 |
Gene Expression/immunology | 2 | 2.0 |
Receptors, Chemokine/*genetics/*immunology | 2 | 100.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Giant Cells/drug effects | 2 | 14.0 |
Disulfides/metabolism | 2 | 5.0 |
Dithiothreitol/pharmacology | 2 | 2.0 |
Virion/pathogenicity | 2 | 40.0 |
Receptors, CXCR4/genetics | 6 | 31.0 |
Chemokines, CC/analysis | 2 | 18.0 |
Interferon Type II/*pharmacology | 4 | 0.0 |
Monocytes/cytology | 5 | 4.0 |
Antibodies, Monoclonal/immunology/metabolism | 3 | 7.0 |
Nucleic Acid Conformation | 5 | 0.0 |
Interferon Type II/biosynthesis/genetics | 4 | 11.0 |
Interleukin-4/biosynthesis/genetics | 2 | 11.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Antigens, CD14/biosynthesis | 2 | 3.0 |
Apoptosis/immunology | 4 | 4.0 |
Binding, Competitive/drug effects | 3 | 4.0 |
Microcirculation/metabolism | 2 | 16.0 |
Antigens, CD45 | 2 | 0.0 |
CD4-Positive T-Lymphocytes/classification/*virology | 2 | 100.0 |
Giant Cells/*virology | 2 | 20.0 |
Receptors, HIV/*genetics | 6 | 60.0 |
T-Lymphocyte Subsets/virology | 2 | 40.0 |
*Chemokines | 2 | 20.0 |
HIV/*metabolism | 3 | 8.0 |
Protein Isoforms | 3 | 0.0 |
CD4-Positive T-Lymphocytes/physiology | 3 | 5.0 |
HIV-2/*pathogenicity | 2 | 33.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
*Receptors, Chemokine | 30 | 32.0 |
Receptors, Cytokine/*genetics | 14 | 24.0 |
Receptors, HIV/metabolism/*physiology | 2 | 100.0 |
T-Lymphocytes/*metabolism/virology | 3 | 37.0 |
Macrophages/drug effects/*virology | 4 | 100.0 |
Monocytes/drug effects/*virology | 3 | 100.0 |
HIV-1/*isolation & purification | 4 | 4.0 |
Receptors, CXCR4 | 11 | 28.0 |
Lymphocytes/metabolism/*virology | 2 | 66.0 |
Macrophages/metabolism/*virology | 8 | 36.0 |
Receptors, HIV/biosynthesis | 4 | 66.0 |
Virus Replication/physiology | 3 | 13.0 |
CD4-Positive T-Lymphocytes/metabolism/*virology | 8 | 47.0 |
Virus Replication/*physiology | 8 | 15.0 |
Gene Therapy | 4 | 1.0 |
*HIV-1/genetics | 2 | 3.0 |
Confidence Intervals | 4 | 1.0 |
Receptors, CCR5/*blood | 3 | 100.0 |
Cytokines/physiology | 6 | 3.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Genetic Vectors/immunology | 2 | 20.0 |
Glucocorticoids/therapeutic use | 3 | 4.0 |
Genes, Reporter/genetics | 4 | 1.0 |
Peptide Fragments/chemistry/genetics/metabolism | 2 | 2.0 |
HIV Seronegativity | 6 | 4.0 |
Leukocytes, Mononuclear/*metabolism | 3 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 2 | 0.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Receptors, Cell Surface/genetics/metabolism | 3 | 4.0 |
Macrophage Inflammatory Protein-1/immunology | 3 | 37.0 |
Receptors, CCR5/genetics/*immunology/metabolism | 2 | 100.0 |
T-Lymphocytes/*immunology/metabolism | 5 | 3.0 |
Callithrix | 2 | 2.0 |
Saimiri | 2 | 6.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
Gene Products, tat/genetics | 2 | 9.0 |
HIV-1/*drug effects/pathogenicity/physiology | 2 | 40.0 |
*Pertussis Toxin | 2 | 6.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Virulence Factors, Bordetella/chemistry/*pharmacology | 2 | 100.0 |
Receptors, CXCR4/drug effects/metabolism | 2 | 33.0 |
HIV-1/immunology/*physiology | 6 | 11.0 |
Lectins/metabolism | 2 | 2.0 |
HIV Infections/*metabolism | 8 | 16.0 |
*Cell Death | 3 | 6.0 |
Mathematics | 2 | 1.0 |
Antiviral Agents/*pharmacology | 6 | 3.0 |
Tyrosine | 2 | 1.0 |
Antigens, CD34/*metabolism | 3 | 2.0 |
Colony-Forming Units Assay | 4 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
HIV Infections/*prevention & control | 6 | 23.0 |
Antigens, CD4/immunology/metabolism | 4 | 16.0 |
*Epitope Mapping | 3 | 5.0 |
Gene Products, env/*immunology | 2 | 8.0 |
*Viral Envelope Proteins | 7 | 15.0 |
Dendritic Cells/*metabolism | 2 | 3.0 |
Chimeric Proteins | 3 | 3.0 |
Acquired Immunodeficiency Syndrome/*genetics | 5 | 41.0 |
Receptors, Cytokine/genetics | 10 | 31.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Gene Products, env/metabolism | 14 | 27.0 |
Leukocytes, Mononuclear/metabolism | 4 | 1.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Receptors, CCR5/deficiency/genetics/physiology | 2 | 100.0 |
Receptors, Cytokine/genetics/*physiology | 2 | 22.0 |
Receptors, Virus/genetics/*physiology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/metabolism/virology | 3 | 23.0 |
RNA, Viral/genetics/metabolism | 2 | 8.0 |
T-Lymphocytes/*metabolism/*virology | 2 | 40.0 |
Cell Culture Techniques/methods | 3 | 1.0 |
HIV-1/*growth & development | 8 | 12.0 |
Macrophages/cytology/virology | 2 | 40.0 |
Chemokines | 2 | 50.0 |
T-Lymphocytes/metabolism/*virology | 3 | 15.0 |
RANTES/analogs & derivatives/pharmacology | 3 | 100.0 |
Receptors, HIV/antagonists & inhibitors/*metabolism | 2 | 100.0 |
HIV Infections/blood/*immunology | 2 | 3.0 |
Receptors, CCR5/blood | 2 | 66.0 |
Receptors, CXCR4/blood | 2 | 50.0 |
Receptors, Chemokine/*blood | 4 | 66.0 |
B-Lymphocytes/metabolism | 4 | 2.0 |
Gene Expression/*drug effects | 3 | 1.0 |
Antigens, CD30/analysis | 2 | 5.0 |
Receptors, Tumor Necrosis Factor/analysis | 2 | 3.0 |
T-Lymphocytes/*chemistry | 2 | 9.0 |
Chemokines, CC/pharmacology | 6 | 19.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology/*virology | 2 | 50.0 |
HIV-1/growth & development/*immunology | 2 | 33.0 |
Macrophage Inflammatory Protein-1/biosynthesis | 7 | 35.0 |
Primates | 4 | 5.0 |
Tumor Necrosis Factor-alpha/*immunology | 2 | 1.0 |
GTP-Binding Proteins | 2 | 28.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/metabolism | 4 | 4.0 |
Pertussis Toxin/pharmacology | 4 | 6.0 |
Rats, Inbred Lew | 4 | 1.0 |
HIV Infections/genetics/immunology | 2 | 33.0 |
India | 5 | 1.0 |
Nucleic Acid Heteroduplexes | 2 | 4.0 |
Receptors, CXCR4/antagonists & inhibitors/genetics/*metabolism | 2 | 50.0 |
Synovial Membrane/*immunology | 3 | 8.0 |
HIV Infections/*immunology/*virology | 4 | 16.0 |
Receptors, Peptide/*metabolism | 2 | 10.0 |
SIV/*metabolism | 9 | 37.0 |
Viral Envelope Proteins/genetics/*metabolism | 3 | 11.0 |
Antigens, Differentiation/*immunology | 2 | 1.0 |
Chemokines, CC/biosynthesis | 2 | 12.0 |
Down-Regulation/immunology | 5 | 5.0 |
Drug Therapy, Combination | 4 | 0.0 |
Reverse Transcriptase Inhibitors/therapeutic use | 2 | 2.0 |
Zidovudine/therapeutic use | 4 | 2.0 |
Antigens, CD4/chemistry/metabolism | 3 | 60.0 |
Cell Membrane/chemistry | 2 | 1.0 |
HIV Envelope Protein gp120/chemistry/metabolism | 3 | 33.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Chromosomes, Human, Pair 3 | 5 | 2.0 |
Sex Factors | 3 | 0.0 |
Antibodies/immunology | 5 | 1.0 |
Membrane Fusion/physiology | 2 | 11.0 |
Viral Envelope Proteins/metabolism | 5 | 9.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
Monocytes/physiology | 3 | 2.0 |
Rats, Nude | 2 | 4.0 |
CD4-Positive T-Lymphocytes/*immunology/pathology/*virology | 2 | 66.0 |
Virus Replication/drug effects/immunology | 2 | 28.0 |
*HIV-2 | 2 | 8.0 |
Senegal | 2 | 6.0 |
HIV-1/*drug effects/growth & development | 2 | 14.0 |
Proviruses | 3 | 17.0 |
RANTES/genetics/*metabolism | 3 | 50.0 |
Cell Membrane/virology | 3 | 18.0 |
Gene Products, env/physiology | 4 | 50.0 |
Drug Resistance, Microbial | 4 | 2.0 |
RANTES/*analogs & derivatives/pharmacology | 3 | 50.0 |
Acquired Immunodeficiency Syndrome/immunology/*virology | 3 | 23.0 |
Chemokines, CC/*physiology | 2 | 14.0 |
Evaluation Studies | 2 | 0.0 |
DNA, Complementary | 5 | 0.0 |
RNA, Viral/metabolism | 4 | 4.0 |
Receptors, Chemokine/blood | 2 | 50.0 |
T-Lymphocytes/chemistry | 2 | 6.0 |
Receptors, CCR5/drug effects/genetics/*physiology | 2 | 100.0 |
Signal Transduction/drug effects | 9 | 1.0 |
RNA Splicing | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Lymphocytes/*immunology | 2 | 0.0 |
HIV Infections/*etiology | 2 | 16.0 |
HIV-1/immunology/physiology | 4 | 40.0 |
Bisexuality | 2 | 10.0 |
HIV-1/pathogenicity | 8 | 40.0 |
HIV/physiology | 3 | 8.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
DNA, Viral/metabolism | 6 | 6.0 |
Luminescent Proteins/genetics/metabolism | 3 | 1.0 |
Viral Proteins/metabolism | 2 | 2.0 |
Virion/physiology | 2 | 8.0 |
Gene Products, tat/*immunology | 2 | 28.0 |
Receptors, CCR5/immunology/*metabolism | 4 | 100.0 |
HIV Infections/complications/virology | 3 | 50.0 |
Receptors, HIV/analysis | 2 | 50.0 |
Blotting, Northern | 3 | 0.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Monocytes/cytology/immunology | 2 | 5.0 |
Receptors, Interleukin/metabolism | 4 | 6.0 |
Receptors, Interleukin-8B | 5 | 45.0 |
HIV-1/*drug effects/isolation & purification | 2 | 28.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
Interleukin-4/biosynthesis | 3 | 2.0 |
Virulence/immunology | 2 | 18.0 |
Receptors, Cell Surface/genetics | 2 | 1.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Macrophages/*immunology/*virology | 2 | 50.0 |
Monocytes/immunology/virology | 2 | 25.0 |
Antigens, CD40/metabolism | 2 | 3.0 |
CD40 Ligand | 3 | 1.0 |
Cell Movement/*immunology | 5 | 7.0 |
Skin/cytology/immunology | 2 | 11.0 |
Nitriles/pharmacology | 2 | 1.0 |
Proviruses/genetics | 2 | 3.0 |
Receptors, CCR5/*genetics/*immunology | 2 | 100.0 |
Th1 Cells/cytology/*immunology | 2 | 20.0 |
Brain/*blood supply | 2 | 6.0 |
Chemotaxis/drug effects/physiology | 2 | 9.0 |
Open Reading Frames | 4 | 0.0 |
Recombinant Proteins/immunology/pharmacology | 2 | 8.0 |
Receptors, CCR5/drug effects/genetics/*metabolism | 2 | 100.0 |
Genetics, Population | 5 | 1.0 |
Caspases/*metabolism | 2 | 0.0 |
Gene Products, env/*physiology | 2 | 40.0 |
Peptide Fragments/genetics/*metabolism | 5 | 18.0 |
Cell Fusion/immunology | 2 | 28.0 |
HIV Infections/*prevention & control/virology | 2 | 40.0 |
Plasmids/genetics | 2 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Receptors, HIV/genetics/*metabolism | 12 | 60.0 |
Macrophages/immunology/*metabolism | 2 | 6.0 |
Receptors, Cytokine/*biosynthesis/genetics | 2 | 22.0 |
Leukocytes, Mononuclear/drug effects/*metabolism | 2 | 5.0 |
B-Lymphocytes/immunology/*virology | 3 | 27.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Leukocytes, Mononuclear/*virology | 4 | 11.0 |
Receptors, CXCR4/*immunology | 6 | 37.0 |
Chromosomes, Human, Pair 3/genetics | 2 | 1.0 |
Genes, Structural | 3 | 0.0 |
Cytokines/*pharmacology | 3 | 0.0 |
*Hemiterpenes | 2 | 28.0 |
Interleukin-12/pharmacology | 4 | 8.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 3 | 6.0 |
Transforming Growth Factor beta/pharmacology | 3 | 0.0 |
Neuroglia/metabolism | 3 | 4.0 |
Receptors, CCR5/metabolism/physiology | 3 | 100.0 |
Receptors, Chemokine/metabolism/*physiology | 3 | 33.0 |
*Receptors, CCR5 | 2 | 66.0 |
United States | 2 | 0.0 |
*Models, Molecular | 2 | 1.0 |
Brazil | 2 | 0.0 |
Gene Products, env/genetics | 2 | 13.0 |
HIV Envelope Protein gp120/immunology/*physiology | 2 | 28.0 |
Quinones/pharmacology | 2 | 1.0 |
Antigens, CD4/genetics/metabolism | 2 | 9.0 |
*HIV-1/isolation & purification | 2 | 8.0 |
Peptides/*metabolism | 3 | 1.0 |
HIV-1/*drug effects/immunology/physiology | 2 | 33.0 |
Edema/etiology | 3 | 21.0 |
Emergency Treatment/methods/psychology | 3 | 75.0 |
Finger Injuries/*etiology/therapy | 3 | 75.0 |
Foreign Bodies/*complications | 3 | 75.0 |
Mental Competency | 3 | 75.0 |
Range of Motion, Articular | 3 | 13.0 |
Schizophrenia/*complications | 3 | 30.0 |
Receptors, Chemokine/biosynthesis/*immunology | 3 | 60.0 |
Chemokines, CC/*genetics | 2 | 6.0 |
Culture Techniques/methods | 2 | 3.0 |
Skin/cytology/virology | 2 | 66.0 |
*Amino Acid Substitution | 2 | 2.0 |
Gene Products, env/*genetics | 2 | 25.0 |
HIV-2/pathogenicity | 2 | 100.0 |
NIH 3T3 Cells | 4 | 1.0 |
SIV/pathogenicity | 3 | 75.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Lectins, C-Type/analysis | 2 | 33.0 |
Mannose-Binding Lectins/analysis | 2 | 66.0 |
Sweden | 2 | 0.0 |
Glomerular Mesangium/*metabolism | 2 | 20.0 |
AIDS Dementia Complex/*etiology/genetics/virology | 2 | 100.0 |
Gene Products, tat/metabolism | 2 | 5.0 |
Alanine/chemistry | 3 | 4.0 |
Chemokines, CC/*secretion | 2 | 100.0 |
Receptors, Antigen, T-Cell/*metabolism | 2 | 1.0 |
Chemotaxis/drug effects/*physiology | 2 | 13.0 |
Peptide Fragments/genetics/immunology | 2 | 5.0 |
Receptors, Cytokine/genetics/metabolism | 4 | 33.0 |
Binding Sites/physiology | 2 | 1.0 |
Culture Media | 2 | 0.0 |
HIV-1/genetics/isolation & purification/*metabolism/physiology | 2 | 100.0 |
RANTES/secretion | 4 | 50.0 |
Acquired Immunodeficiency Syndrome/virology | 4 | 21.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
Dendritic Cells/*immunology/*metabolism | 2 | 11.0 |
Lung/*immunology | 2 | 4.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Chemotaxis/*immunology | 2 | 28.0 |
HIV Envelope Protein gp120/*physiology | 5 | 16.0 |
Protein Isoforms/metabolism | 2 | 1.0 |
HIV Antigens/metabolism | 2 | 20.0 |
HIV Seropositivity/immunology | 3 | 3.0 |
RANTES/*metabolism | 6 | 42.0 |
Antibodies, Monoclonal/*immunology | 5 | 0.0 |
Antigens, CD28/*immunology | 3 | 2.0 |
Microspheres | 2 | 1.0 |
HIV-1/*immunology/isolation & purification/metabolism | 2 | 100.0 |
Leukocytes, Mononuclear/immunology/virology | 3 | 27.0 |
Receptors, CCR5/*biosynthesis/*genetics | 2 | 100.0 |
Th2 Cells/immunology | 9 | 5.0 |
HIV-1/*genetics/isolation & purification/pathogenicity | 2 | 66.0 |
*Heterosexuality | 2 | 28.0 |
Chemokines/genetics | 2 | 11.0 |
Macrophage Activation/*drug effects | 2 | 5.0 |
Interleukin-8/biosynthesis/genetics | 2 | 8.0 |
Quinolinic Acid/*pharmacology | 2 | 40.0 |
HIV/drug effects/*physiology | 2 | 28.0 |
Heterocyclic Compounds/*pharmacology | 3 | 20.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
HIV-1/*immunology/metabolism | 3 | 37.0 |
Virus Inhibitors/*physiology | 2 | 16.0 |
HIV Envelope Protein gp120/physiology | 4 | 22.0 |
Disease Susceptibility/immunology | 7 | 10.0 |
Chemokines, CC/*metabolism/pharmacology | 3 | 50.0 |
T-Lymphocytes/immunology/*virology | 3 | 18.0 |
Receptors, Chemokine/*biosynthesis/physiology | 5 | 55.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 2 | 3.0 |
Receptors, CCR5/*antagonists & inhibitors/physiology | 2 | 100.0 |
Arrestins/metabolism | 2 | 15.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 3 | 1.0 |
GTP-Binding Proteins/*metabolism | 3 | 0.0 |
Open Reading Frames/genetics | 2 | 1.0 |
Macrophage Activation | 4 | 2.0 |
Receptors, CCR5/*chemistry/genetics/*physiology | 2 | 100.0 |
Receptors, HIV/*antagonists & inhibitors | 4 | 57.0 |
Receptors, HIV/*analysis | 2 | 40.0 |
HIV Infections/immunology/*virology | 5 | 14.0 |
Receptors, CCR5/*biosynthesis/blood | 4 | 100.0 |
SIV/isolation & purification/*metabolism/physiology | 2 | 100.0 |
HIV-1/isolation & purification/*physiology | 4 | 20.0 |
HIV Envelope Protein gp120/chemistry/*immunology | 2 | 14.0 |
Immunosuppression | 2 | 1.0 |
Receptors, CCR5/biosynthesis/*immunology | 2 | 100.0 |
Signal Transduction/drug effects/immunology | 2 | 4.0 |
Acquired Immunodeficiency Syndrome/*genetics/immunology | 2 | 40.0 |
Receptors, CXCR4/metabolism/physiology | 2 | 100.0 |
Allosteric Regulation | 2 | 3.0 |
Receptors, CCR5/antagonists & inhibitors | 4 | 44.0 |
Fetal Blood/cytology | 3 | 1.0 |
Anti-HIV Agents/metabolism/*pharmacology | 2 | 14.0 |
Chemotaxis/*drug effects | 4 | 8.0 |
Brain/*metabolism | 2 | 0.0 |
Brain/cytology/metabolism | 2 | 5.0 |
Cervix Uteri/secretion/*virology | 2 | 66.0 |
Antigens, CD4 | 2 | 2.0 |
Macrophages/cytology/drug effects/metabolism/*virology | 3 | 100.0 |
Peptide Fragments/*metabolism | 3 | 2.0 |
Receptors, Interleukin-8A | 2 | 6.0 |
HIV Envelope Protein gp160/genetics/*metabolism | 2 | 33.0 |
Viral Envelope Proteins/physiology | 2 | 20.0 |
RNA, Viral/*analysis | 2 | 3.0 |
Sexual Partners | 2 | 10.0 |
Embryo | 2 | 0.0 |
Cell Membrane/physiology | 2 | 1.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Forskolin/pharmacology | 2 | 0.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Brain/cytology/*virology | 2 | 66.0 |
Phosphoproteins/metabolism | 3 | 0.0 |
Fetal Blood/cytology/immunology | 2 | 5.0 |
Receptors, Lymphocyte Homing/metabolism | 3 | 8.0 |
Receptors, CXCR4/*genetics | 7 | 26.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
SIV/isolation & purification/*physiology | 2 | 66.0 |
CD4-Positive T-Lymphocytes | 7 | 2.0 |
Gene Products, env/chemistry/*genetics/metabolism | 2 | 50.0 |
RANTES/analogs & derivatives | 2 | 66.0 |
Serotyping | 2 | 0.0 |
HIV-1/*drug effects/immunology | 2 | 18.0 |
Up-Regulation/drug effects/immunology | 2 | 5.0 |
Tropism/*physiology | 2 | 50.0 |
Th2 Cells/*metabolism | 2 | 8.0 |
Leukocytes, Mononuclear/metabolism/virology | 2 | 25.0 |
Base Pairing | 2 | 3.0 |
HLA-DR Antigens/genetics | 2 | 0.0 |
Macrophages, Alveolar/metabolism/*virology | 3 | 75.0 |
Immunity, Natural/*genetics | 2 | 12.0 |
Cell Survival/immunology | 3 | 5.0 |
HIV Envelope Protein gp120/drug effects/metabolism | 3 | 50.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 3 | 6.0 |
Epitope Mapping | 2 | 0.0 |
HIV-1/*drug effects/genetics/metabolism | 2 | 33.0 |
Viral Envelope Proteins/genetics | 3 | 13.0 |
Restriction Mapping | 2 | 0.0 |
Central Nervous System/*metabolism | 2 | 5.0 |
Neurons/metabolism | 3 | 0.0 |
Membrane Glycoproteins/*physiology | 2 | 0.0 |
Receptors, CXCR4/chemistry/physiology | 3 | 100.0 |
Macrophages/*metabolism/virology | 3 | 42.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
RANTES/cerebrospinal fluid | 2 | 66.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
HIV Infections/genetics/*virology | 2 | 66.0 |
Virus Replication/*genetics | 3 | 9.0 |
Receptors, Cytokine/*physiology | 3 | 11.0 |
Immunodeficiency Virus, Feline/*physiology | 2 | 50.0 |
Receptors, Chemokine/genetics/physiology | 3 | 60.0 |
Viremia/immunology | 3 | 15.0 |
Continental Population Groups | 2 | 1.0 |
Homosexuality | 2 | 1.0 |
Endosomes/metabolism | 2 | 1.0 |
*Genetic Markers | 2 | 0.0 |
Probability | 3 | 0.0 |
Receptors, Chemokine/*genetics/metabolism | 4 | 28.0 |
Denmark | 3 | 1.0 |
Binding Sites/drug effects/immunology | 2 | 25.0 |
Down-Regulation/drug effects/immunology | 2 | 10.0 |
Macrophage Inflammatory Protein-1/immunology/metabolism | 2 | 66.0 |
Stereoisomerism | 3 | 0.0 |
Amino Acids/chemistry | 2 | 1.0 |
T-Lymphocytes/*immunology/*virology | 2 | 20.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Lymphoid Tissue/*metabolism | 2 | 14.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
*Genetic Vectors | 3 | 0.0 |
Receptors, CCR5/analysis/genetics/*physiology | 2 | 100.0 |
Receptors, Cytokine/physiology | 2 | 7.0 |
Receptors, Peptide/physiology | 2 | 25.0 |
Hematopoietic Stem Cells/*immunology/*virology | 2 | 66.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Indicators and Reagents | 2 | 0.0 |
HIV Infections/*genetics/mortality | 2 | 100.0 |
Heterozygote Detection | 3 | 0.0 |
Spleen/immunology | 2 | 1.0 |
Monocyte Chemoattractant Proteins/metabolism | 2 | 22.0 |
Cell Movement/physiology | 3 | 1.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Receptors, CXCR4/*antagonists & inhibitors/metabolism | 2 | 33.0 |
SIV/genetics/*metabolism/physiology | 2 | 100.0 |
*Protein Conformation | 3 | 1.0 |
RNA, Viral | 2 | 4.0 |
HIV-1/drug effects/*pathogenicity | 3 | 60.0 |
CD8-Positive T-Lymphocytes/*immunology/virology | 2 | 11.0 |
Macaca nemestrina | 2 | 6.0 |
Microglia/physiology/*virology | 2 | 100.0 |
HIV Envelope Protein gp160/immunology | 2 | 20.0 |
*HIV-1/immunology | 3 | 9.0 |
Macrophage Inflammatory Protein-1/*immunology | 2 | 100.0 |
RANTES/*immunology | 2 | 50.0 |
Genes, Dominant | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/*genetics/*immunology | 2 | 100.0 |
HIV Infections/*genetics/*immunology | 3 | 37.0 |
Leukocyte Count | 3 | 0.0 |
Th1 Cells/immunology/*metabolism | 2 | 25.0 |
Th2 Cells/immunology/*metabolism | 2 | 16.0 |
Endothelium, Vascular/cytology/virology | 2 | 100.0 |
Proteoglycans/*metabolism | 2 | 3.0 |
Astrocytes/metabolism | 2 | 2.0 |
HIV Envelope Protein gp41/metabolism | 2 | 8.0 |
Virion/metabolism | 2 | 5.0 |
Sequence Homology | 3 | 0.0 |
Receptors, Peptide/genetics/metabolism | 2 | 16.0 |
Monocytes/drug effects/*physiology | 2 | 5.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Receptors, CXCR4/*biosynthesis/immunology | 3 | 50.0 |
Russia | 3 | 3.0 |
AIDS-Related Opportunistic Infections/virology | 2 | 50.0 |
Receptors, Chemokine/analysis/*biosynthesis | 2 | 50.0 |
HIV-1/genetics/*pathogenicity/*physiology | 2 | 33.0 |
HIV Infections/genetics/virology | 2 | 100.0 |
HIV-1/isolation & purification/*pathogenicity/physiology | 2 | 100.0 |
Gene Therapy/methods | 2 | 2.0 |
Receptors, CXCR4/*biosynthesis/blood | 2 | 100.0 |
Cytokines/*physiology | 2 | 1.0 |
Leukocytes/metabolism | 4 | 2.0 |
Cell Fusion/drug effects | 2 | 10.0 |
Stromal Cells/metabolism | 2 | 2.0 |
DNA | 5 | 0.0 |
Cell Fusion/physiology | 2 | 22.0 |
HIV Envelope Protein gp120/chemistry/*metabolism | 2 | 15.0 |
Receptors, CXCR4/immunology/*metabolism | 2 | 33.0 |
Acquired Immunodeficiency Syndrome/pathology | 2 | 16.0 |
HIV/pathogenicity | 2 | 20.0 |
Receptors, CXCR4/drug effects/genetics/*physiology | 2 | 40.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Mucous Membrane/immunology | 2 | 7.0 |
Cytokines/*biosynthesis | 2 | 0.0 |
Biotinylation | 2 | 1.0 |
*Peptide Library | 2 | 3.0 |
Receptors, CCR5/*immunology/metabolism | 2 | 100.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Receptors, Chemokine/biosynthesis/*metabolism | 2 | 40.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Second Messenger Systems | 2 | 2.0 |
HIV/immunology | 2 | 3.0 |
Lymphocyte Subsets | 2 | 1.0 |
Brain/metabolism | 2 | 0.0 |
Microglia/metabolism | 2 | 8.0 |
Vaccination | 2 | 1.0 |
Brain Chemistry/*immunology | 2 | 33.0 |
Simian Acquired Immunodeficiency Syndrome/immunology/*virology | 2 | 33.0 |
Antigens, Differentiation/immunology | 2 | 1.0 |
Receptors, Virus/immunology | 2 | 15.0 |
HIV Infections/*genetics/immunology/physiopathology | 2 | 66.0 |
Interleukin-15/pharmacology | 2 | 8.0 |
Macrophages/*physiology/*virology | 2 | 66.0 |
Crystallization | 2 | 0.0 |
HIV-1/*chemistry/immunology | 2 | 22.0 |
GTP-Binding Proteins/physiology | 2 | 3.0 |
*Selection (Genetics) | 3 | 4.0 |
DNA, Viral/genetics/metabolism | 2 | 6.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Autoantibodies/blood | 2 | 1.0 |
HL-60 Cells | 4 | 0.0 |
Antigens/administration & dosage | 2 | 11.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Macrophages/*immunology | 2 | 0.0 |
Receptors, CCR5/deficiency/genetics/*physiology | 2 | 100.0 |
Receptors, HIV/*genetics/physiology | 2 | 66.0 |
DNA Footprinting | 2 | 0.0 |
Monocytes/metabolism/*virology | 2 | 33.0 |
Hepacivirus/*immunology | 2 | 6.0 |
*SIV | 3 | 27.0 |
HIV-1/genetics/isolation & purification/*metabolism | 2 | 50.0 |
*Chemokines, CXC | 10 | 15.0 |
Leukocytes, Mononuclear/cytology/metabolism | 2 | 12.0 |
Epithelial Cells/virology | 4 | 25.0 |
Cytokines/metabolism/pharmacology | 2 | 11.0 |
RNA/genetics/metabolism | 3 | 1.0 |
Signal Transduction/genetics/*immunology | 2 | 2.0 |
Receptors, CCR5/chemistry/*genetics | 2 | 66.0 |
HIV Envelope Protein gp41/pharmacology | 2 | 50.0 |
HIV-2/*metabolism | 3 | 21.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
HIV Envelope Protein gp160/metabolism | 2 | 25.0 |
Receptors, Chemokine/*analysis/genetics | 3 | 37.0 |
Lymphoma, T-Cell | 2 | 10.0 |
Receptors, CXCR4/*antagonists & inhibitors/immunology | 2 | 100.0 |
HIV-1/immunology/metabolism | 2 | 40.0 |
Models, Structural | 4 | 2.0 |
Membrane Proteins/*physiology | 2 | 1.0 |
Fibrosis | 3 | 2.0 |
Gene Products, env/genetics/*metabolism | 3 | 25.0 |
Receptors, Cytokine/genetics/*metabolism | 5 | 16.0 |
Chemotactic Factors, Eosinophil/metabolism | 2 | 33.0 |
Macrophages/physiology | 2 | 2.0 |
Dendritic Cells/virology | 4 | 40.0 |
Virus Replication/drug effects/*physiology | 3 | 60.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
Macrophages/physiology/*virology | 2 | 66.0 |
Receptors, HIV/biosynthesis/chemistry/*physiology | 2 | 100.0 |
*Immunity, Natural | 2 | 3.0 |
Receptors, Cytokine/*immunology | 3 | 33.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism/*virology | 3 | 60.0 |
Interleukin-2/immunology | 2 | 1.0 |
Acquired Immunodeficiency Syndrome/metabolism | 2 | 15.0 |
Receptors, HIV/genetics/immunology/*metabolism | 2 | 66.0 |
Multigene Family | 2 | 0.0 |
Cytokines/*genetics | 3 | 2.0 |
Receptors, Cytokine/chemistry/genetics/*metabolism | 2 | 33.0 |
Gene Products, gag/biosynthesis | 2 | 25.0 |
Skin/immunology | 2 | 2.0 |
Chemokines, CC/*metabolism/physiology | 2 | 50.0 |
Inflammation/immunology/metabolism | 2 | 11.0 |
Macromolecular Substances | 3 | 0.0 |
Culture Media, Conditioned/pharmacology | 3 | 1.0 |
Receptors, CXCR4/genetics/immunology/*metabolism | 3 | 100.0 |
Macrophages/chemistry/virology | 2 | 100.0 |
Cytomegalovirus/immunology | 3 | 4.0 |
HIV-1/*drug effects/pathogenicity | 2 | 40.0 |
Receptors, CCR5/antagonists & inhibitors/genetics | 2 | 100.0 |
Anti-HIV Agents/*chemical synthesis/chemistry/*pharmacokinetics | 2 | 100.0 |
Piperidines/*chemical synthesis/chemistry/*pharmacokinetics | 2 | 100.0 |
Pyrazoles/chemistry/pharmacokinetics | 2 | 100.0 |
Cell Cycle Proteins/*metabolism | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Leukocytes/cytology/*metabolism | 2 | 50.0 |
Tumor Necrosis Factor-alpha/analysis | 3 | 0.0 |
Drug Industry | 2 | 11.0 |
Calcium/immunology | 2 | 20.0 |
RNA/chemistry/genetics | 2 | 7.0 |
Antibody Formation/immunology | 2 | 4.0 |
Immunity, Natural/immunology | 2 | 8.0 |
CD4-Positive T-Lymphocytes/*metabolism/*virology | 2 | 100.0 |
Mice, Inbred Strains | 2 | 0.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Piperidines/chemistry/pharmacology | 2 | 40.0 |
*Genetics, Population | 2 | 0.0 |
Haplotypes/*genetics | 2 | 1.0 |
Fluorescent Antibody Technique/methods | 2 | 5.0 |
*RNA Interference | 2 | 5.0 |
Circumcision | 2 | 100.0 |
Remission Induction | 2 | 0.0 |
Comorbidity | 2 | 0.0 |
RNA-Binding Proteins/metabolism | 2 | 2.0 |
Chemokines/*analysis/genetics | 2 | 100.0 |
Macrophages/immunology | 3 | 1.0 |
Cell Adhesion Molecules/*immunology | 2 | 3.0 |
Cell Survival/drug effects | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Cytokines/*blood | 2 | 0.0 |
Autoimmune Diseases/*immunology/pathology | 2 | 12.0 |
Crosses, Genetic | 2 | 0.0 |
Australia | 2 | 1.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Antiviral Agents/therapeutic use | 2 | 1.0 |
HIV Infections/*drug therapy/immunology/virology | 2 | 1.0 |
Chemokines/genetics/*immunology | 2 | 100.0 |
Acquired Immunodeficiency Syndrome/prevention & control | 2 | 16.0 |
HIV Core Protein p24/genetics | 2 | 18.0 |
Receptors, CCR5/analysis/metabolism | 2 | 100.0 |
Sampling Studies | 2 | 1.0 |
Receptors, Chemokine/*biosynthesis/blood | 2 | 28.0 |
T-Lymphocytes/immunology/*metabolism | 2 | 2.0 |
Flavonoids/pharmacology | 2 | 0.0 |
*Receptors, Prostaglandin | 2 | 33.0 |
Peptides/metabolism | 2 | 0.0 |
Langerhans Cells/physiology | 2 | 40.0 |
HIV Envelope Protein gp120/*chemistry/metabolism | 2 | 16.0 |
Receptors, HIV/immunology/*physiology | 2 | 100.0 |
Immunotherapy/*methods | 2 | 1.0 |
Heart Transplantation/*immunology | 2 | 3.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Receptors, CCR5/antagonists & inhibitors/genetics/*physiology | 2 | 100.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
Alanine Transaminase/blood | 2 | 1.0 |
DNA, Viral/*blood | 2 | 5.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Microcirculation | 2 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Galactosylceramides/metabolism | 2 | 14.0 |
Receptors, Cytokine/biosynthesis/genetics | 2 | 33.0 |
South Africa | 4 | 2.0 |
Lymphocyte Subsets/immunology | 2 | 1.0 |
Antibodies/pharmacology | 2 | 0.0 |
Receptors, CCR5/analysis/biosynthesis | 2 | 100.0 |
Clone Cells/immunology | 2 | 1.0 |
Plasmids | 2 | 0.0 |
Hepacivirus/isolation & purification | 2 | 12.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Europe/ethnology | 2 | 2.0 |
Analgesics, Opioid/pharmacology | 3 | 27.0 |
Cell Fractionation | 2 | 0.0 |
Receptors, Opioid, delta/*metabolism | 2 | 40.0 |
Receptors, Opioid, mu/*metabolism | 2 | 33.0 |
Inflammation | 2 | 0.0 |
Virus Assembly | 2 | 7.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
Receptors, CCR5/genetics/*immunology | 2 | 66.0 |
